U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

WHO Guidelines on Use of Medically Important Antimicrobials in Food-Producing Animals. Geneva: World Health Organization; 2017.

Cover of WHO Guidelines on Use of Medically Important Antimicrobials in Food-Producing Animals

WHO Guidelines on Use of Medically Important Antimicrobials in Food-Producing Animals.

Show details

1.2Restriction in the use of antibiotics in food animals and antibiotic resistance in food animals and humans – a systematic review and meta-analysis (University of Calgary, Canada)

, , , , , , , , , , and .

Author Information and Affiliations

Last Revision: March 2017.

Background:

Antibiotics are the cornerstone of therapy for bacterial infectious diseases in humans and animals. The One Health approach recognizes that the health of humans, animals, and the environment are intricately linked, that the use of antibiotics in animals select for resistant bacteria, and that bacteria and their resistant genetic elements can be transmitted cross-species from animals to humans. The rise in resistance to antibiotics is therefore a threat to public health globally and there is a growing recognition that we may need to use antibacterial agents in a more judicious way. In this systematic review and meta-analysis, commissioned by the World Health Organization, we sought to summarize the evidence on the effect that interventions that reduce antibiotic use in food animals has on the presence of antibiotic resistant bacteria and resistant genetic elements in animals and in humans.

Methods:

We conducted a comprehensive search of electronic databases (including Agricola, AGRIS, BIOSIS Previews, CAB Abstracts, MEDLINE, EMBASE, Global Index Medicus, ProQuest Dissertations, and Science Citation Index) in July 2016, with an update in January 2017. In addition, we reviewed conference proceedings of major scientific meetings on antibiotic resistance and conducted a thorough grey literature search that included governmental websites from a wide range of regions globally. Inclusion criteria were original studies that reported on any interventions that aimed to reduce antibiotic use in food animals and compared presence of antibiotic resistant bacteria or genetic resistance elements between intervention and comparator groups in food animals or in humans. Analysis was conducted and reported separately for animals and humans. We pooled studies that reported an absolute risk difference in the prevalence of resistance in bacteria isolated from intervention compared to control groups using DerSimonian and Laird random-effects models. Meta-analysis for animals was conducted separately for different antibiotic classes for six different bacteria and sample type combinations, while meta-analysis for humans was not stratified due to smaller numbers of studies. Studies reporting on genetic elements of resistance and studies that could not be meta-analyzed (because they reported on different units of analyses or did not provide risk differences) were described qualitatively.

Results:

A total of 5,945 unique records were identified and screened. Of these, 386 were reviewed at the full-text stage. In total, 181 studies were included in the systematic review. Of these, 179 described antibiotic resistance outcomes in animals, of which 81 were meta-analyzed. Twenty-one studies described antibiotic resistance outcomes in humans (19 of which also reported antibiotic resistance in animals), of which 13 were meta-analyzed. The pooled absolute risk reduction of the prevalence of antibiotic resistance in animals, with interventions that restricted antibiotic use, varied across different antibiotic classes, bacteria, and sample types, but ranged from 0% to 39%; in general, the prevalence of antibiotic resistance was commonly 10–20% lower in intervention compared to control groups. The pooled prevalence of multi-drug resistance was 24–32% lower in bacteria isolated from intervention groups. These findings held through many different layers of stratification including by intervention type. Similarly, for humans, the pooled prevalence of antibiotic resistance was 24% lower in intervention groups (where interventions to reduce antibiotic use in food animals were implemented) compared to control groups. The effect was similar, albeit weaker, when considering humans without direct contact with livestock animals, compared to farm workers.

Conclusion:

There is a large body of evidence that, when pooled, consistently shows that interventions that restrict the use of antibiotics in food animals are associated with a reduction in the presence of antibiotic resistant bacteria in these animals. Our analysis also suggests that there may be a reduction in the number of antibiotic resistant bacteria in human populations with these interventions, with the greatest effect for those in direct contact with animals. These findings are in keeping with One Health phenomena and the understanding that animals and humans share the same environment, and they suggest that the effects of restricting antibiotic use in animals on antibiotic resistance may extend beyond the animals themselves.

Acknowledgements

We would like to thank the following for their support during this project:

  • Drs. Carl Ribble (University of Calgary), John Prescott (University of Guelph), Karen Liljebjelke (University of Calgary), Sylvia Checkley (University of Calgary), Tim McAllister (Agriculture and Agri-Food Canada), and Vic Gannon (Public Health Agency of Canada) for their feedback and guidance regarding antimicrobial resistance.
  • Jay Son (Sunnybrook Research Institute), Julia Kupis (W21C, University of Calgary), and Zoe Thomson (W21C, University of Calgary) along with Drs. Caroline Ritter (University of Calgary), David Hall (University of Calgary), Jan Tomka (NAFC-RIAP Nitra), Karin Lienhard (W21C, University of Calgary), and Lis Alban (Danish Agriculture and Food Council) for their assistance with language translation of studies not available in English.
  • Jill de Grood and the W21C Research and Innovation Centre for project coordination and oversight.
  • Canadian Institutes of Health Research and Alberta Innovates – Health Solutions for their support through Dr. Karen Tang’s fellowship awards.

Abbreviations

AGISAR

Advisory Group on Integrated Surveillance of Antimicrobial Resistance

AGP

antimicrobial growth promoter

AMR

antimicrobial resistance

AMU

antimicrobial use

CI

confidence interval

CIA

Critically Important Antimicrobials

DALY

disability adjusted life years

DANMAP

Danish Integrated Antimicrobial Resistance Monitoring and Research Programme

FAO

Food and Agriculture Organization

GRADE

grading of recommendations assessment, development and evaluation

MARAN

Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands

MeSH

medical subject heading

MIC

minimum inhibitory concentration

MRSA

methicillin resistant Staphylococcus aureus

N/A

not application

NR

not reported

OIE

World Organization of Animal Health

OR

odds ratio

PICOD

populations, intervention, control/comparator, outcome, design

PRISMA

preferred reporting items for systematic reviews and meta-analyses

RAB

reduced antibiotic farms

RAB-CD

reduced antibiotic with cleaning and disinfection protocol farms

RCT

randomized controlled trials

RD

risk difference

UK

United Kingdom

USA

United States

WHO

World Health Organization

WHO

FERG World Health Organization Foodborne Diseases Epidemiology Reference Group

Introduction

In this report, we present a systematic review on the effect of interventions that restrict the use of one or more antibiotics in food animals on the prevalence of antibiotic resistant bacteria in food animals and humans. This review has been commissioned to inform the development of a proposed WHO Guideline on the use of antibiotics in food animals, which may then serve to inform policy makers and regulatory officials on this important issue (1).

Antimicrobial agents are commonly used in livestock agriculture and aquaculture for therapeutic and non-therapeutic indications (24). These include treatment of active infections, prevention of infections in the absence of active disease, and for growth promotion. Though antimicrobial agents include drugs to treat viral, fungal, bacterial, and parasitic diseases, we have been asked to focus on antibiotics, or antibacterial drugs, for the purposes of this review.

As we gain more insight into the complexity of antibiotic resistance, there is recognition that anthropogenic activities and the wide use of antibiotics in human medicine and animal agriculture have contributed to the growing genetic pool of resistance genes found in bacteria isolated from humans, animals, and the environment (58). There is a growing concern that the routine use of antibiotics in food animals provides strong evolutionary pressure for potentially zoonotic bacteria to develop resistance to antibiotics commonly used to treat humans (2, 9, 10). Pathogenic (e.g., Salmonella spp., Campylobacter spp.) and commensal (e.g., Escherichia coli, Enterococcus spp.) bacteria, including those carrying resistance genes, can be transmitted from animals to humans through food, as well as by direct contact with animals, or through environmental sources such as contaminated water. As a result, national and international antimicrobial resistance (AMR) monitoring programs have been implemented to assess and monitor the extent of this problem (1114). Many countries have also enforced a ban on the use of specified antimicrobial agents in the feed of food animals (15).

Recognizing that the use of antibiotics in food animals may lead to broader public health consequences, the WHO created the list of Critically Important Antimicrobials for human medicine (CIA) (10, 16). This list classifies antimicrobials by level of importance in human medicine; it serves to prioritize the preservation of the effectiveness of antibiotics that are most important in the treatment of human infections. There is a need for recommendations on the use and restrictions of antibiotics in food animals, which specifically considers the antibiotics in the WHO CIA list. This forms the basis of the proposed WHO Guideline, the development of which may be informed by this systematic review.

There is consensus that the use of antibiotics is prevalent in food animals and that this leads to the development of antibiotic resistance in these animals. Furthermore, food animals are a source of antibiotic resistant bacteria for humans, which may then cause significant disease, morbidity, and mortality. There is, however, not consensus regarding the level of impact that antibiotic use in food animals has on antibiotic resistance in the general human population. The issue of antibiotic resistance is highly complex with a number of different biological drivers involved in the selection and persistence of antibiotic resistance genes both in the natural environment and in the presence of antibiotic use (5, 17). In this systematic review and meta-analysis, we have been asked to address the following two research questions, as articulated by the WHO terms of reference (1):

a. Research question one (PICOD 1)

For food animal populations of any age in any setting, does a restriction compared to not having that restriction of use of antimicrobial agent(s) in food animals reduce the presence of antimicrobial-resistant genetic elements and/or antimicrobial resistant bacteria in food animal populations?

b. Research question two (PICOD 2)

For human populations of any age in any setting, does a restriction compared to not having that restriction of use of antimicrobial agent(s) in food animals reduce the presence of antimicrobial-resistant genetic elements and/or antimicrobial resistant bacteria in human populations?

Methods

a. Search strategy

We performed this systematic review and meta-analysis using a predetermined protocol with strategic input from members of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) and in accordance with published guidelines for reporting in systematic reviews and meta-analyses (18). We identified all potentially relevant articles regardless of publication language by searching the following electronic databases:

  • Agricola – Ebsco Platform (1970–present)
  • BIOSIS Previews – Web of Knowledge Platform (1980–present)
  • CAB Abstracts – Ebsco Platform (1910–present)
  • MEDLINE – Ovid Platform (Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946–present)
  • EMBASE – Ovid Platform (1974–present)
  • Global Index Medicus (http://www.globalhealthlibrary.net/): The non-MEDLINE indices included: AIM (AFRO), LILACS (AMRO/PAHO), IMEMR (EMRO), IMSEAR (SEARO), WPRIM (WPRO), WHOLIS (KMS), and SciELO.
  • ProQuest Dissertations – ProQuest Platform
  • Science Citation Index – Web of Knowledge Platform (1899–present)

A research librarian with expertise in the aforementioned databases (HG) developed the search strategy and derived three comprehensive search themes related to the populations of interest (theme 1), antimicrobial agents and drug/antimicrobial resistance (theme 2), and relevant interventions (theme 3). These three comprehensive search themes were comprised of both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Heading), and keywords and were then combined using the Boolean operator “and” in varying combinations. Antibiotic-related keywords for theme 2 were derived from the WHO list of Critically Important Antimicrobials for Human Medicine (19) and the World Organisation for Animal Health (OIE) List of Antimicrobial Agents of Veterinary Importance (20). The search strategy was peer-reviewed by a research librarian within the University of Calgary and was reviewed for content by a WHO librarian (Tomas Allen). Appendix 1 outlines the full Medline search strategy, which was modified as appropriate for other databases.

The electronic database search was enhanced by scanning bibliographies of relevant review articles and articles included into this systematic review that were published between 2010–2016, as well as by reviewing conference proceedings from major scientific meetings. Grey literature (as defined by literature produced on all levels of government, academics, business, and industry in print and electronic formats, but not controlled by commercial publishers) was identified by searching websites of relevant health agencies, professional associations, and other specialized databases. Google and Google Scholar and other internet search engines were searched for additional information. See Appendix 2 for a comprehensive list of sources and a detailed outline of the search strategy used for the grey literature. Finally, experts in the field were contacted regarding missed, ongoing, or unpublished studies.

b. Screening of abstracts for eligibility

Two individuals (KT and NC) independently reviewed all identified abstracts for eligibility using predefined criteria. Specifically, all abstracts that (a) reported on original research, (b) described an intervention that aimed to limit antibiotic use in animals, and (c) described antibiotic resistance in animals or humans were selected for full-text review. This initial stage was intentionally liberal. We only discarded abstracts that clearly did not meet the aforementioned criteria. Disagreements were resolved by consensus or third-party consultation (SC) when consensus could not be achieved.

c. Full-text review of articles

The same reviewers then performed a full-text review of articles that met the inclusion criteria. Both published and unpublished studies were eligible for inclusion. Articles were retained if they met the following PICOD criteria for research questions 1 and 2:

Populations:

  1. Food-producing animals of any age falling under any of the following classifications: avian, swine, bovine, caprine, camel, equine, rabbit, ovine, fish, bees, molluscs, and crustaceans
  2. Humans of any age

Intervention: A restriction of use of one or more antibiotics in food-producing animals.

Any level of restriction was considered, including complete cessation of the use of one or more antibiotics. All types of restrictions were considered, whether externally imposed by regulatory authorities or governments, or voluntary at the farm or industry level. Examples of restrictions that were considered included: any prohibition on the use of antibiotics, such as but not limited to prohibition of use for specific indications (e.g., for growth promotion or prophylaxis of disease), requirement of a prescription by a veterinarian for the use of antibiotics, organic interventions, or voluntary restrictions on farms. Additional limitations not listed above (e.g., changes to guidelines regarding preferential antibiotic use, enhanced surveillance and reporting, enhanced stewardship, innovation through research and development, and incentives for reduced antibiotic use) were considered eligible for inclusion if there was demonstrated reduction in antibiotic use.

Control/Comparator: Not having a restriction on the use of antibiotics in food animals.

Outcome:

  1. The presence of antibiotic resistant bacteria and/or antibiotic resistant genetic elements and/or changes to antibiotic susceptibility (i.e. minimum inhibitory concentrations) in food-producing animal populations. All bacterial species from all possible sample types (e.g., faeces, cloacal swabs, caecal swabs, meat or carcasses, milk, eggs, nasal swabs, etc.) were considered.
  2. The presence of antibiotic resistant bacteria and/or antibiotic resistant genetic elements and/or changes to antibiotic susceptibility (i.e. minimum inhibitory concentrations) in human populations. All bacterial species from all possible sample types were considered.

Design: Original studies, including both interventional and observational studies, with a comparator/control group

Studies conducted at the individual and country/area level (ecological) were considered. The comparator/control group did not have to be an external group. That is, studies with historical comparators were considered eligible for inclusion into the systematic review. Examples of included study designs were: randomized controlled trials (RCTs), non-randomized controlled trials, controlled and uncontrolled pre-post (before and after) studies, prospective cohort studies with concurrent control group, interrupted time-series and repeated measures studies, cross-sectional, and ecological studies (where there was a comparison of intervention versus comparator regions or farms). Interrater agreement for inclusion into the systematic review at the full-text review stage was good (κ=0.74).

d. Data extraction and assessment of individual study quality

Data from individual studies were extracted by KT and NC using a predesigned data extraction form. The following data elements were extracted: author, year, study design, country, species and age of animal, number of farms/animals used in analysis, sample type (e.g., faeces, solid meat, etc.), sampling point (e.g., farm, slaughter, retail), description of intervention, description of comparator, antibiotic panels, laboratory procedure, and bacteria investigated. The outcome variables of interest were the prevalence of antibiotic resistant bacteria and/or antibiotic resistant genetic elements and/or changes to antibiotic susceptibility in intervention and control groups in both animals and human subjects. Before data from all studies were extracted, the data extraction form was piloted by having the two reviewers extract data in duplicate for the first 10 individual studies (in alphabetical order). The data extracted were reviewed by two content experts on the team (SC and HB). There were no significant differences in the extracted data and no modifications to the data extraction form were required.

The same two reviewers (KT and NC) also independently assessed the methodological quality of individual studies based on pre-specified study quality indicators adapted from the Downs and Black checklist (21). These items were used to assess the overall quality of reporting, external validity (generalizability), and internal validity (sources of bias) and helped inform the assessment of the global quality of the evidence (GRADE tables described below). Quality assessments were done in duplicate and any disagreements were resolved through consensus.

e. Analysis: Animal studies

Recognizing the variability in reporting with respect to study populations, interventions, outcomes of interest, and measures of association reported, we conducted four concurrent analyses for animal studies (PICOD 1).

i. First analysis: Meta-analysis for specific bacteria and sample types

We conducted a series of meta-analyses for all studies that reported differences in proportions as the common measure of association. Specifically, we pooled studies that reported an absolute risk difference in the prevalence of antibiotic resistance in bacteria isolated from intervention compared to control groups using DerSimonian and Laird random-effects models (22). Based on this metric, a pooled negative result would indicate a lower prevalence of antibiotic resistance in the intervention group compared to the control group, whereas a positive result would indicate a higher prevalence of antibiotic resistance in the intervention group compared to the control group. A random effects model was felt necessary a priori regardless of actual heterogeneity of findings because the studies were known to be clinically heterogeneous, evaluating a variety of interventions across different regions globally, resulting in random effects rather than a fixed true effect across all studies. With a large number of studies, the overall power for finding statistical heterogeneity across studies was high, further highlighting the need for the use of random effects models.

Given the number of bacterial species, sample types, and antibiotic classes that could be investigated, we made an a priori decision to conduct pooled analyses within six bacterial/sample type groups:

  1. Enterobacteriaceae in faecal samples (Enterobacteriaceae family most commonly included Escherichia coli, Salmonella spp., or unspecified Enterobacteriaceae)
  2. Enterobacteriaceae in meat samples
  3. Enterococcus spp. in faecal samples
  4. Campylobacter spp. in faecal samples
  5. Campylobacter spp. in meat samples
  6. Staphylococcus spp. in milk samples

These divisions were made due to fundamental differences in these bacterial groups in terms of their microbiologic characteristics, innate antibiotic resistance, and potential for pathogenicity. Furthermore, milk, faecal, and meat samples are inherently different in terms of common bacterial species that are isolated. They are also subject to different environments and processes that may result in differing levels of baseline resistance. This was the rationale for our six separate analytic groupings. Within each of these groups, separate meta-analyses were conducted for different antibiotic classes and also for multi-drug resistance. Meta-analysis was only performed if there were six or more studies that reported risk differences in a specific antibiotic class or for multi-drug resistance, and if the studies fell within one of the six bacterial and sample type categories mentioned above. The threshold of six studies for meta-analysis was chosen because between-study variance cannot be estimated accurately with five or fewer studies, which may then lead to biased pooled estimates when meta-analysis using the DerSimonian and Laird approach is undertaken (23). The quality of studies did not determine whether they were eligible for inclusion into meta-analyses; all studies that provided the necessary data to conduct meta-analysis within any one of the six bacterial and sample groupings were included. The effect of study quality on meta-analytic results was assessed using stratified analysis (see “Second analysis: Global meta-analysis section” below). The unit of analysis was at the isolate level for individual studies. When studies provided multiple point estimates (i.e. multiple antibiotics that fell within the same antibiotic class, multiple bacterial species that fell within the same genus, or multiple measures across different geographic regions), a fixed effect model with inverse variance weighting was used to generate a single point estimate per antibiotic class per study. Similarly, for longitudinal study designs with repeated measures of antibiotic resistance, the first and last data points were used to calculate risk differences within intervention and control groups.

To visually assess the pooled absolute risk difference estimates and corresponding 95% confidence intervals (CIs), forest plots were generated. Heterogeneity across studies was also evaluated using the Q statistic (significance level of p≤0.10) and the I2 statistic (24, 25). Recognizing that within and between-study variability would be substantial, we stratified our results by intervention type.

ii. Second analysis: Global meta-analysis

We performed a “global meta-analysis,” which included all animal studies amenable to meta-analysis, ignoring specific bacterial species, sample types, units of analysis, and antibiotic classes, for the purposes of stratifying by quality criteria and assessing publication bias only. A single effect estimate (absolute risk difference) was generated for each study by conducting within-study meta-analysis using random effects models. This within-study meta-analysis allowed us to pool the risk difference in the prevalence of antibiotic resistance in bacteria isolated from intervention and control groups, across all tested antibiotics, all bacterial groups, and all sample types tested. We recognized that the pooled effect estimate for each study and the pooled effect estimate across all studies would not be meaningful due to the diversity of sample types, bacteria, antibiotics, and units of analysis pooled. Rather, a global meta-analysis resulted in the inclusion of more studies and thus greater power for stratified analysis by quality criteria. This stratified analysis assessed whether there was a significant difference in the pooled effect estimates in studies that met quality criteria (higher quality studies) compared to those that did not meet quality criteria (lower quality studies). Stratification was performed for three study quality criteria felt to be of highest importance:

  1. Were animals included in the intervention and control group recruited from the same source population?
  2. Were animals included in the intervention and control group recruited over the same period of time?
  3. Was there adequate adjustment for important confounders in the analysis?

In addition, stratified analysis was performed for studies published in peer-reviewed journals versus non peer-reviewed articles (including abstracts and reports). Meta-regression was used to determine if the above four factors were significant predictors of the underlying heterogeneity.

Finally, global meta-analysis allowed assessment of publication bias as it provided a “big picture” view of all current studies examining changes to antibiotic resistance in food animals when antibiotic use is reduced. The concern about publication bias is not whether there is publication bias in each of the six specific groups of samples and bacteria that we analyzed, but rather whether there is publication bias in this entire research area, irrespective of the bacterial type, sample type, and specific antibiotic classes that are studied. Assessment of publication bias was therefore performed using all studies amenable to meta-analysis, without differentiating into the six previously described bacterial and sample groups. Publication bias was assessed using Begg’s test in addition to the visual inspection of a funnel plot (26). Sensitivity analysis using the Duval and Tweedie nonparametric “trim and fill” procedure was also implemented if there was any suggestion of visual asymmetry on the funnel plots (27). This method considers the possibility of hypothetical “missing” studies that might exist, imputes their risk difference, and recalculates a pooled risk difference that incorporates the hypothetical studies as though they actually existed.

iii. Third analysis: Qualitative description of study results reporting phenotypic resistance

For studies that could not be included within the formal meta-analysis outlined above (described in the section “First analysis”), a semi-quantitative analysis was completed to visualize trends in phenotypic antibiotic resistance across bacterial categories (Campylobacter spp., Enterobacteriaceae, Enterococcus spp., Staphylococcus spp., other) and antibiotic classes. Results from individual studies were coded as green (lower prevalence of antibiotic resistance in intervention compared to control group), yellow (no difference in prevalence of antibiotic resistance between the intervention and control group) and red (higher prevalence of antibiotic resistance in intervention compared to control group). A series of decision rules were created to reduce the results into these three categories for each study:

  1. If the prevalence of resistance rates to different antibiotics within the same antibiotic class were all lower or higher in the intervention compared to the control group, the antibiotic class received a green or red mark respectively.
  2. If there were discordant results within an antibiotic class (i.e. there was lower resistance in the intervention group to certain antibiotics, but higher resistance to other antibiotics in the same antibiotic class) this antibiotic class received a yellow mark.
  3. If there were some antibiotics that showed no difference in results across intervention and controls, while other antibiotics within the same antibiotic class showed lower or higher resistance in the intervention compared to the control group, they received a green or red mark respectively.
  4. If a study did not specify the antibiotic class and simply reported on overall antibiotic resistance, they were color coded according to this overall result across all antibiotic classes and marked with an asterisk.

All decisions were corroborated by author conclusions and presence of reported statistical testing (p-values and/or 95% CIs) to determine if there was statistically significant differences between intervention and control groups.

iv. Fourth analysis: Qualitative description of study results reporting genotypic resistance

Finally, studies that reported on genetic elements, as they related to antibiotic resistance, were analyzed separately. Studies that reported on virulent genetic elements were not included within this analysis. Results were presented in two separate tables. The first summarized individual studies with respect to intervention type, population, bacteria investigated, and genes screened. A subsequent table was created to outline the numbers of studies that reported higher, lower, or no difference in prevalence of resistant genetic elements between intervention and control groups. The proportion of isolates with resistant genetic elements in the intervention versus the control group was extracted from each study. Statistical testing using Fisher’s exact test (significance level of p<0.05) was then conducted to determine whether differences in prevalence of resistant genetic elements between the intervention and comparator groups were significant. If data were not available to conduct these statistical tests, author conclusions were used. Results were stratified by whether authors used targeted screening (where gene detection methods were applied only to resistant isolates) versus non-targeted screening (where gene detection methods were applied to all isolates).

e. Analysis: Human studies

Due to the low numbers of human studies (addressing PICOD 2) and the relative homogeneity of these studies compared to the animal studies, a single meta-analysis was conducted regardless of sample type, bacteria isolated, and antibiotics tested. Random effects models were again used for the same reasons described above. The unit of analysis was the sample rather than the isolate, as most human studies reported sample-level data. Stratified meta-analysis was performed by population type (individuals with direct contact to food animals such as farm workers, versus individuals without direct contact to such animals), to explore whether the associations between restriction in antibiotic use in animals and reduction in antibiotic resistance in humans were limited to specific human subpopulations. Publication bias was assessed using the same method as for animal studies, with Begg’s test in addition to the visual inspection of the funnel plot (26). For the studies that could not be meta-analyzed due to insufficient data, a narrative synthesis of each study was also included. A qualitative description of study results reporting genotypic resistance data was included within the same tables as the animal studies (see above “Fourth analysis: Qualitative description of study results reporting genotypic resistance”).

f. GRADE tables

Judgments around the global quality of evidence required assessments of the validity of the results of individual studies for the outcomes of interest. Explicit criteria were used in making these judgments. Specifically, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group has developed a standardized and transparent methodology for assessing the global quality of evidence (28). This approach has been adopted by a number of agencies and decision-making groups, including the WHO.

The quality of the outcome measures was assessed by using a standard GRADE approach as described by Guyatt et al. (29). The GRADE evidence tables for the primary outcome (absolute risk difference in the prevalence of antibiotic resistance in bacteria isolated from intervention compared to control groups) were prepared for animal and human studies separately. For animal studies, although a number of stratifications was available for presentation, for brevity we limited our strata to those identified as highest priority/critically important antimicrobials as outlined by the WHO (30). As described in GRADE methodology, evidence derived from RCTs starts as high quality evidence and observational studies as low quality evidence supporting estimate of intervention effects (Table 1).

Table 1. Quality assessment criteria adapted from Guyatt (2011) (29).

Table 1

Quality assessment criteria adapted from Guyatt (2011) (29).

Five factors were assessed to potentially downgrade the evidence (risk of bias, inconsistency, indirectness, imprecision, and publication bias), while three factors were assessed to potentially upgrade the level of evidence (large effect, dose response, all plausible confounders or biases would result in an underestimate of the effect size). Overall, the quality of evidence for the primary outcome could fall into one of four categories including very low, low, moderate, and high. Using a consensus approach, all investigators were involved in the judgement of upgrading or downgrading the level of evidence and providing detailed reasons for doing so in the GRADE tables and accompanying notes.

Results

a. Identification of studies

The initial search strategy identified a total of 9,008 citations. An additional 56 were identified by contacting experts in the field of antibiotic use and resistance, and another 82 were identified through searching the reference lists of studies that were included in this systematic review. From these, 3,201 duplicates were removed, and 5,945 records were screened for eligibility through title and abstract review. After removal of the 5,559 records that were not relevant to either of the two research questions, 386 full-text articles were reviewed. Of these, a total of 181 studies addressed either PICOD 1 or PICOD 2 and were therefore included in the systematic review (15, 31210). The most common reasons for exclusion of articles at the full-text review stage were the absence of interventions that aimed to reduce antibiotic use in animals and the absence of a comparator group (see Figure 1 for full PRISMA flow diagram).

Figure 1. Flow diagram of the study selection process.

Figure 1

Flow diagram of the study selection process.

Of the 181 studies, 160 reported on the outcome of antibiotic resistance in animals only, two reported on the outcome of antibiotic resistance in humans only, and 19 included both outcomes. That is, 179 studies addressed the first research question (PICOD 1) (15, 31108, 110161, 163206210), while 21 studies addressed the second research question (PICOD 2) (51, 62, 66, 7274, 78, 90, 98, 100, 107, 109, 111, 112, 151, 162, 179, 181, 184, 196, 197). The results from the animal studies and human studies are reported separately. There were 19 studies that addressed both PICOD 1 and PICOD 2 and were included in both animal and human analyses.

b. Animal studies

i. Study characteristics

Of the 179 animal studies, 148 were articles in peer-reviewed journals, 20 were abstracts only without accompanying full-text articles, nine were dissertations, and two were government or organization reports. Poultry was the most commonly studied animal population, followed by swine and dairy cattle (see Table 2 for a summary of study characteristics and Table 3 for detailed characteristics of individual studies).

Table 2. Summary of study characteristics for animal studies.

Table 2

Summary of study characteristics for animal studies.

Table 3. Study characteristics of individual animal studies.

Table 3

Study characteristics of individual animal studies.

Interventions were classified into four categories: 1) Externally imposed bans or restrictions of antibiotic use (n=36 studies); 2) Organic interventions, as defined by the study and the country-specific regulations for organic certification (n=87 studies); 3) Self-reported and self-labeling of antibiotic-free and related interventions, such as free-range or pasture (n=38 studies); and 4) Voluntary reduction or cessation of antibiotic use (n=29 studies). These intervention categories were not mutually exclusive. For example, studies that reported antibiotic resistance in antibiotic-free versus organic versus conventional meats were considered to include both “Organic” and “Antibiotic-Free” interventions.

A variety of samples were tested for antibiotic resistance across studies. Most commonly, studies used faecal or caecal samples (n=106 studies), followed by meat or carcass samples (n=53 studies). In addition, a wide variety of bacteria were studied including Campylobacter spp., Enterococcus spp., Enterobacteriaceae family of bacteria, and Staphylococcus spp. See Appendix 3 for flow charts illustrating the sample points, sample types, and bacteria studied for each of the four classes of interventions.

Studies were predominantly from the United States (n=81). A large number of studies were European in origin (n=78), with many of these comparing antibiotic resistance across different European countries. The countries in Europe with greatest representation were Denmark (n=21) and Spain (n=11). Few studies originated from Asia (n=6) and only one study was from Africa. Five studies did not specify the country of origin (Figure 2).

Figure Icon

Figure 2

Geographic representation of countries* from which animal studies (human studies in parentheses) originate, with enlarged European insert. (The global map is currently being reproduced and to be uploaded in due course)

ii. Study quality

Study quality was assessed for all 179 studies that examine antibiotic resistance in animals (Table 4).

Table 4. Assessment of study quality for individual animal studies.

Table 4

Assessment of study quality for individual animal studies.

Table 5. Proportion of studies meeting study quality criteria.

Table 5

Proportion of studies meeting study quality criteria.

An area of weaker study quality was the general lack of description of the study populations and management practices on farms and slaughterhouses. Without a clear description of sample characteristics, it was often difficult to assess whether intervention and control groups were comparable and whether they were representative of the source population. There also tended to be a lack of description of the interventions that aimed to reduce antibiotic use in animals, specifically in studies that sampled at the retail level (e.g., studies that compared antibiotic resistance in retail meats labeled as organic or antibiotic-free or other related labels versus conventional meats). For labels without rigorous requirements or certification such as for pasture-raised, free-range, or raised without antibiotics, the label itself, without a clear description of the underlying farm management practices, provides no detail regarding co-interventions and degree of antibiotic use, such as whether antibiotics are allowed therapeutically. For studies with organic interventions, many studies again tended to use the term “organic” to describe the intervention without any other detail, and despite rigorous processes for certification, this label alone is an inadequate description of the intervention, given that organic requirements are generally country or region-specific. Furthermore, few studies adjusted for potential confounders, despite the many variables that are likely to confound the complex association between antibiotic resistance and antibiotic use in animals. To address these study quality limitations, we conducted stratified analysis based on study quality criteria to determine whether there were any differences in pooled effect estimates for higher versus lower quality studies (see section “Stratified analysis: study quality criteria”).

iii. Synthesis of results

Of the 179 studies reporting antibiotic resistance in animals, 81 were included in meta-analyses. Because of the heterogeneity of the studies, with different bacteria, sample types (faeces versus carcass versus milk samples), and sample points (farm versus slaughter versus retail), we chose to conduct a series of meta-analyses rather than pooling all studies simultaneously in a single meta-analysis. We pooled the absolute risk differences in antibiotic resistance for individual antibiotic classes for: 1) Enterobacteriaceae in faecal samples; 2) Enterobacteriaceae in meat samples; 3) Enterococcus spp. in faecal samples; 4) Campylobacter spp. in faecal samples; 5) Campylobacter spp. in meat samples; and 6) Staphylococcus spp. in milk samples.

1. Enterobacteriaceae in faecal samples

The Enterobacteriaceae are a large family of bacteria, though all studies that were meta-analyzed reported antibiotic resistance for only three groups: 1) E. coli, 2) Salmonella spp., and 3) non-specified faecal coliforms. The most commonly studied bacterial species was E. coli. Depending on the antibiotic class, absolute risk differences in antibiotic resistance in Enterobacteriaceae were pooled for 16 to 21 studies (Table 6).

Table 6. Pooled absolute risk differences of antibiotic resistance for Enterobacteriaceae isolates in faecal samples.

Table 6

Pooled absolute risk differences of antibiotic resistance for Enterobacteriaceae isolates in faecal samples.

All pooled estimates across antibiotic classes were less than zero, indicating that the pooled risk of antibiotic resistance in the intervention group was lower than that in the control group. These were statistically significant, with the upper limit of the 95% confidence interval not crossing 0, for all antibiotic classes except for cephalosporins and quinolones. The pooled absolute risk difference of antibiotic resistance was highest for tetracyclines at −0.16 (95% CI −0.27, −0.05). This corresponds to a 16% reduction in the percentage of isolates that are antibiotic resistant in the intervention group compared to the control group. The pooled absolute risk difference was lowest for cephalosporins and quinolones at −0.01 (95% CI −0.04, 0.01) and −0.01 (95% CI −0.02, −0.00) respectively, corresponding to a 1% reduction in the percentage of isolates that are antibiotic resistant in the intervention group compared to the control group for both antibiotic classes. See Appendix 4 Figures 17 for forest plots of absolute risk differences of antibiotic resistance for each of the seven classes of antibiotics. There was significant heterogeneity across studies, with an I2 between 92.8% and 99.3% and Cochran Q test p-values <0.05 for all antibiotic classes for which meta-analysis was undertaken. Meta-analysis was not undertaken for the following antibiotic classes due to insufficient numbers of studies: aminocyclitols (2 studies), carbapenems (1 study), nitrofurantoins (2 studies), and polymyxins (4 studies).

Figure 1. Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Enterobacteriaceae isolates in faecal samples.

Figure 1

Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Enterobacteriaceae isolates in faecal samples.

Figure 7. Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Enterobacteriaceae isolates in faecal samples.

Figure 7

Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Enterobacteriaceae isolates in faecal samples.

A meta-analysis of 19 studies reporting multi-drug resistance to antibiotics was also conducted. The pooled absolute risk difference of multi-drug resistance was −0.24 (95% CI −0.32, −0.17). That is, the pooled proportion of isolates that were resistant to multiple antibiotics was 24% lower in intervention groups compared to control groups (Figure 3).

Figure 3. Forest plot of absolute risk differences of multi-drug resistance for Enterobacteriaceae isolates in faecal samples.

Figure 3

Forest plot of absolute risk differences of multi-drug resistance for Enterobacteriaceae isolates in faecal samples.

2. Enterobacteriaceae in meat samples

Similar to faecal samples, all studies of Enterobacteriaceae in meat samples studied E. coli, Salmonella spp., or unspecified coliforms. Depending on the antibiotic class, the absolute risk differences in antibiotic resistance in Enterobacteriaceae were pooled for 11 to 13 studies (Table 7).

Table 7. Pooled absolute risk differences of antibiotic resistance for Enterobacteriaceae isolates in meat samples.

Table 7

Pooled absolute risk differences of antibiotic resistance for Enterobacteriaceae isolates in meat samples.

All pooled estimates across antibiotic classes were less than zero, indicating that the pooled risk of antibiotic resistance in the intervention group was lower than that in the control group. These were statistically significant for all antibiotic classes except for cephalosporins (risk difference −0.07 [95% CI −0.14, 0.01]). The pooled absolute risk difference of antibiotic resistance was highest for sulfonamides at −0.23 (95% CI −0.32, −0.13). See Appendix 4 Figures 814 for forest plots of absolute risk differences of antibiotic resistance for each of the seven classes of antibiotics. There was significant heterogeneity across studies, with an I2 between 82.3% and 97.9% and Cochran Q test p-value <0.05 for all studies for which meta-analysis was undertaken. Meta-analysis was not undertaken for the following antibiotic classes due to insufficient numbers of studies: carbapenems (1 study), cyclic esters (3 studies), macrolides (1 study), and nitrofurantoins (5 studies).

Figure 8. Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Enterobacteriaceae isolates in meat samples.

Figure 8

Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Enterobacteriaceae isolates in meat samples.

Figure 14. Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Enterobacteriaceae isolates in meat samples.

Figure 14

Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Enterobacteriaceae isolates in meat samples.

In addition, a meta-analysis of 14 studies reporting multi-drug resistance to antibiotics was conducted. The pooled absolute risk difference of multi-drug resistance was −0.32 (95% CI −0.43, −0.22). That is, the proportion of isolates that were resistant to multiple antibiotics was 32% lower in intervention groups compared to control groups (Figure 4).

Figure 4. Forest plot of absolute risk differences of multi-drug resistance for Enterobacteriaceae isolates in meat samples.

Figure 4

Forest plot of absolute risk differences of multi-drug resistance for Enterobacteriaceae isolates in meat samples.

3. Enterococcus spp. in faecal samples

For Enterococcus spp. in faecal samples, depending on the antibiotic class, the absolute risk differences in antibiotic resistance were pooled for 7 to 12 studies (Table 8).

Table 8. Pooled absolute risk differences of antibiotic resistance for Enterococcus spp. isolates in faecal samples.

Table 8

Pooled absolute risk differences of antibiotic resistance for Enterococcus spp. isolates in faecal samples.

Similar to the faecal and meat samples for Enterobacteriaceae, all pooled estimates across antibiotic classes were less than zero, indicating that the pooled risk of antibiotic resistance in the intervention group was lower than that in the control group. These were statistically significant for all antibiotic classes. The pooled absolute risk difference of antibiotic resistance was highest for macrolides at −0.39 (95% CI −0.56, −0.23). It was the lowest for penicillins, though the absolute risk difference was still −10% for this antibiotic class (−0.10 [95% CI −0.18, −0.02]). See Appendix 4 Figures 1520 for forest plots of absolute risk differences of antibiotic resistance for each of the six classes of antibiotics. There was significant heterogeneity across studies, with an I2 between 96.4% and 98.8% and Cochran Q test p-value <0.05 for all studies for which meta-analysis was undertaken. No meta-analysis of multi-drug resistance to antibiotics was conducted due to insufficient numbers of studies reporting this outcome. Meta-analysis was also not undertaken for the following antibiotic classes due to insufficient numbers of studies: amphenicols (5 studies), carbapenems (1 study), cyclic esters (1 study), cyclic polypeptides (2 studies), glycylcyclines (1 study), lincosamides (3 studies), lipopeptides (1 study), nitrofurantoins (3 studies), oxazolidinones (2 studies), quinolones (3 studies), and rifamycins (1 study).

Figure 15. Forest plot of absolute risk differences in antibiotic resistance to aminoglycosides for Enterococcus spp. isolates in faecal samples.

Figure 15

Forest plot of absolute risk differences in antibiotic resistance to aminoglycosides for Enterococcus spp. isolates in faecal samples.

Figure 20. Forest plot of absolute risk differences in antibiotic resistance to tetracyclines for Enterococcus spp. isolates in faecal samples.

Figure 20

Forest plot of absolute risk differences in antibiotic resistance to tetracyclines for Enterococcus spp. isolates in faecal samples.

4. Campylobacter spp. in faecal samples

Depending on the antibiotic class, the absolute risk differences in antibiotic resistance were pooled for 7 to 11 studies (Table 9).

Table 9. Pooled absolute risk differences of antibiotic resistance for Campylobacter spp. isolates in faecal samples.

Table 9

Pooled absolute risk differences of antibiotic resistance for Campylobacter spp. isolates in faecal samples.

Similar to the previous meta-analyses, nearly all pooled estimates across antibiotic classes were less than zero, indicating that the pooled risk of antibiotic resistance in the intervention group was lower than that in the control group. However, this was statistically significant only for macrolides (pooled absolute risk difference of −0.15 [95% CI −0.26, −0.04]) and tetracyclines (pooled absolute risk difference of −0.12 [95% CI −0.20, −0.03]). See Appendix 4 Figures 2126 for forest plots of absolute risk differences of antibiotic resistance for each of the six classes of antibiotics. There was significant heterogeneity across studies, with an I2 between 77.5% and 99.4% and Cochran Q test p-value <0.05 for all studies for which meta-analysis was undertaken. Meta-analysis was not undertaken for multi-drug antibiotic resistance or for resistance to the following antibiotic classes due to insufficient numbers of studies: carbapenems (1 study), cephalosporins (1 study), cyclic esters (1 study), lincosamides (3 studies), nitrofurantoins (1 study), oxazolidinones (1 study), and sulfonamides (3 studies).

Figure 21. Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Campylobacter spp. isolates in faecal samples.

Figure 21

Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Campylobacter spp. isolates in faecal samples.

Figure 26. Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Campylobacter spp. isolates in faecal samples.

Figure 26

Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Campylobacter spp. isolates in faecal samples.

5. Campylobacter spp. in meat samples

Meta-analyses were conducted only for three antibiotic classes, due to insufficient numbers of studies reporting resistance to the other antibiotic classes (aminoglycosides [5 studies], amphenicols [5 studies], penicillins [3 studies], and sulfonamides [1 study]). Seven studies reporting on antibiotic resistance to macrolides were pooled, nine were pooled for quinolones, and seven were pooled for tetracyclines. The pooled absolute risk difference for both macrolides and quinolones were less than 0, although neither was statistically significant (−0.04 [95% CI −0.17, 0.09], Appendix 4 Figure 27 for macrolides; −0.08 (95% CI −0.17, 0.01], Appendix 4 Figure 28 for quinolones). The pooled absolute risk difference for tetracyclines was approximately 0 (0.01 [95% CI −0.19, 0.21; Appendix 4 Figure 29) indicating that there was no difference in the pooled risk of antibiotic resistance in the intervention group compared to the control group for this antibiotic class. There was significant heterogeneity, with an I2 between 94.1% and 97.2%. Cochran Q test p-values were all <0.05. No meta-analysis of multi-drug resistance to antibiotics was conducted due to insufficient numbers of studies reporting this outcome.

Figure 27. Forest plot of absolute risk differences of antibiotic resistance to macrolides for Campylobacter spp. isolates in meat samples.

Figure 27

Forest plot of absolute risk differences of antibiotic resistance to macrolides for Campylobacter spp. isolates in meat samples.

Figure 28. Forest plot of absolute risk differences of antibiotic resistance to quinolones for Campylobacter spp. isolates in meat samples.

Figure 28

Forest plot of absolute risk differences of antibiotic resistance to quinolones for Campylobacter spp. isolates in meat samples.

Figure 29. Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Campylobacter spp. isolates in meat samples.

Figure 29

Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Campylobacter spp. isolates in meat samples.

6. Staphylococcus spp. in milk samples

Depending on the antibiotic class, the absolute risk differences in antibiotic resistance were pooled for 6 to 10 studies (Table 10).

Table 10. Pooled absolute risk differences in antibiotic resistance for Staphylococcus spp. isolates in milk samples.

Table 10

Pooled absolute risk differences in antibiotic resistance for Staphylococcus spp. isolates in milk samples.

Similar to the meta-analyses for Enterobacteriaceae and Enterococcus spp., all pooled estimates across antibiotic classes were less than zero, indicating that the pooled risk of antibiotic resistance in the intervention group was lower than in the control group. This was statistically significant for all antibiotic groups except aminoglycosides. The pooled absolute risk difference of antibiotic resistance was highest for lincosamides at −0.09 (95% CI −0.16, −0.02). It was the lowest, and also not statistically significant, for aminoglycosides at −0.04 (95% CI −0.13, 0.05). See Appendix 4 Figures 3035 for forest plots of absolute risk differences of antibiotic resistance for each of the six classes of antibiotics. For most antibiotic classes, there was significant heterogeneity across studies, with an I2 between 78.6% and 91.3%. However, there was very little visual or statistical heterogeneity for the antibiotic class of sulfonamides only, with an I2 of 0.0% and p-value for Cochran Q Test of 0.68. Meta-analysis was not undertaken for multi-drug antibiotic resistance or for resistance to the following antibiotic classes due to insufficient numbers of studies: amphenicols (4 studies), cephalosporins (4 studies), cyclic polypeptides (1 study), glycopeptides (3 studies), nitrofurantoins (1 study), oxazolidinones (1 study), pseudomonic acids (1 study), quinolones (5 studies), rifamycins (2 studies), steroid antibacterials (1 study), and streptogramins (2 studies).

Figure 30. Forest plot of absolute risk differences in antibiotic resistance to aminoglycosides for Staphylococcus spp. isolates in milk samples.

Figure 30

Forest plot of absolute risk differences in antibiotic resistance to aminoglycosides for Staphylococcus spp. isolates in milk samples.

Figure 35. Forest plot of absolute risk differences in antibiotic resistance to tetracyclines for Staphylococcus spp. isolates in milk samples.

Figure 35

Forest plot of absolute risk differences in antibiotic resistance to tetracyclines for Staphylococcus spp. isolates in milk samples.

iv. Stratified analysis by intervention type

Due to the heterogeneity of interventions and results across studies, stratified analysis was performed by intervention type. This was done for Enterobacteriaceae in faecal samples (Appendix 4 Figures 3642), Enterococcus spp. in faecal samples (Appendix 4 Figures 4349), and Campylobacter spp. in faecal samples (Appendix 4 Figures 5055). Overall, there were no clear patterns that emerged from these stratified meta-analyses. That is, absolute risk differences of antibiotic resistance were similar across all intervention types, with no one intervention being consistently associated with a higher or lower absolute risk difference when compared to the others. Of note, there were no external bans or regulation type interventions for studies reporting outcomes in Enterobacteriaceae in faecal samples. There were no voluntary restriction interventions for studies reporting outcomes in Enterococcus spp. or Campylobacter spp. in faecal samples.

Figure 36. Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Enterobacteriaceae isolates in faecal samples, stratified by intervention.

Figure 36

Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Enterobacteriaceae isolates in faecal samples, stratified by intervention.

Figure 42. Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Enterobacteriaceae isolates in faecal samples, stratified by intervention type.

Figure 42

Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Enterobacteriaceae isolates in faecal samples, stratified by intervention type.

Figure 43. Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 43

Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 49. Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 49

Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 50. Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 50

Forest plot of absolute risk differences of antibiotic resistance to aminoglycosides for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 55. Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 55

Forest plot of absolute risk differences of antibiotic resistance to tetracyclines for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Despite stratification by intervention type, visual and statistical heterogeneity remained high, indicating that intervention type alone did not explain the heterogeneity of results. Stratified analysis was not performed for Enterobacteriaceae or Campylobacter spp. in meat samples as these studies consisted primarily of a single intervention type (organic intervention). Similarly, all studies included in meta-analysis for Staphylococcus spp. in milk samples represented organic interventions, so stratified analysis could not be performed in this group either.

v. Stratified analysis by quality criteria

Of our component-based assessment of study quality (see “Study quality” below), the three criteria deemed most important were the following:

  • Were animals in the intervention and comparison groups recruited from the same source population?
  • Were animals included in the intervention and comparison groups recruited over the same period of time?
  • Was there adequate adjustment of important potential confounders?

Due to the low numbers of studies meeting any of these three quality criteria, stratified meta-analysis within the six meta-analytic groups based on bacteria and sample type was not possible. We therefore performed a global meta-analysis for all animal studies that contained the necessary data for meta-analysis, using a pooled single effect estimate for each study (pooling within studies across all antibiotic classes, sample types, and bacterial groups). Stratification and meta-regression based on each of these three quality criteria, in addition to whether studies were published as full-text articles in peer-reviewed journals, was conducted to determine whether there was a difference in the pooled effect estimates between higher quality studies (i.e. studies meeting each of these quality criteria) and lower quality studies (Table 11).

Table 11. Stratified analysis and meta-regression of pooled absolute risk differences in overall antibiotic resistance.

Table 11

Stratified analysis and meta-regression of pooled absolute risk differences in overall antibiotic resistance.

Overall, meta-analyses of both higher quality and lower quality studies demonstrated statistically significant risk reductions in antibiotic resistance in intervention compared to control groups, although effect estimates appeared to be lower for higher quality compared to lower quality studies for the three quality criteria. On meta-regression, however, none of these differences were statistically significant. There did not appear to be any differences in the effect estimates when analysis was stratified for studies that were published as full-text articles in peer-reviewed journals compared to non peer-reviewed articles such as meeting abstracts and reports found in the grey literature.

vi. Publication bias

A funnel plot was produced, including all animal studies that were meta-analyzed. Visual inspection of the funnel plot did reveal visual asymmetry (Figure 5), although Begg’s test for funnel plot asymmetry was not statistically significant (p=0.16).

Figure 5. Funnel plot for animal studies included in meta-analysis.

Figure 5

Funnel plot for animal studies included in meta-analysis.

The visual asymmetry of the funnel plot suggested the potential for publication bias, despite the non-significant results on statistical testing, and therefore, sensitivity analysis using the trim and fill method was performed. There was no change in the risk reduction of antibiotic resistance in animals with interventions that reduced antibiotic use with and without imputation (both −0.13 [95% CI −0.15, −0.11]), suggesting that publication bias, if present, likely had minimal effect on our findings. Of note, the pooled risk difference seen on the funnel plot is −0.03 rather than at −0.13 as the creation of the funnel plot required the use of a fixed effects model (which gives a pooled effect estimate of −0.03). We prefer the use of a random effects model (which gives a pooled effect estimate of −0.13), recognizing the heterogeneity across studies in terms of interventions, regions, bacterial species, and antibiotics tested.

There are other factors that can contribute to funnel plot asymmetry other than publication bias. These include heterogeneity, such as when the magnitude of effect differs based on sample sizes and when there are differences in baseline antibiotic risk across studies. Given the known clinical heterogeneity of studies, with variable sample sizes, animal and bacterial groups studied, samples studied, and countries studied (all leading to probable differences in baseline risk), the funnel plot asymmetry is therefore not surprising and may not be attributable to publication bias alone.

vii. Qualitative description of study results

We conducted a qualitative descriptive analysis of the 63 studies that examined phenotypic antibiotic resistance in animals, which could not be included into the series of meta-analyses. Table 12 summarizes the study results, where red represents higher, green indicates lower, and yellow indicates no difference in the prevalence of antibiotic resistance in the intervention group compared to the comparator group respectively.

Table 12. Trends in the prevalence of antibiotic resistance by bacterial class for studies not included in meta-analyses.

Table 12

Trends in the prevalence of antibiotic resistance by bacterial class for studies not included in meta-analyses.

The results of this analysis very closely reflected the findings from the series of meta-analyses described previously. The summary of the trends found in these 63 studies was:

  1. The majority of studies of antibiotic resistance in animals focused on Enterobacteriaceae.
  2. For Enterobacteriaceae, Enterococcus spp., and Staphylococcus spp., the majority of studies reported a reduction in the absolute risk difference of antibiotic resistance with any intervention that aimed to reduce antibiotic use in animals, across all antibiotic classes and sample types. There were also a large number of studies that reported no statistically significant difference between intervention and control groups, and proportionately few studies that reported an increase of antibiotic resistance with interventions that aimed to reduce antibiotic use in animals.
  3. Antibiotic resistance in Campylobacter spp. appeared to follow a different pattern compared to the other bacterial groups. Specifically, in most studies, no statistically significant difference in antibiotic resistance was detected in animals with interventions that reduced antibiotic use. There were only a small numbers of studies showing decreased antibiotic resistance with interventions that aimed to reduce antibiotic use in animals.

viii. Synthesis of results from studies reporting genetic elements

Fifty-four studies reported genotypic resistance results. See Table 13 for a description of the study characteristics, genes that were screened, and author conclusions on the genetic data for each of these studies.

Table 13. Study characteristics and conclusions from studies that report on genotypic resistance.

Table 13

Study characteristics and conclusions from studies that report on genotypic resistance.

Of these 54 studies, 46 reported the prevalence of genetic resistance elements in intervention groups compared to control groups or provided data where this could be calculated (Table 14).

Table 14. Summary of results for the 46 studies reporting prevalence of resistance genes in intervention versus control groups.

Table 14

Summary of results for the 46 studies reporting prevalence of resistance genes in intervention versus control groups.

These 46 studies reported changes in antibiotic resistance genes with interventions that reduce antibiotics in food animals, shedding light on the mechanisms of antibiotic resistance. The 17 animal studies that performed genetic screening for both phenotypically susceptible and resistant isolates reported a total of 264 associations; 58 of these demonstrated lower prevalence of resistance genes in intervention compared to control groups, while 201 demonstrated no statistically significant difference in prevalence of resistance genes between the groups. These results corroborate the findings from the meta-analyses and the qualitative description of phenotypic results; a considerable number of studies showed that interventions that reduce antibiotic use in food animals also reduced resistance genes, especially those genes that are associated with the restricted drug. For some genes such as blashv, tetB, tetQ, this association was supported by two or more studies. Almost no studies showed an increase in resistance genes with interventions that reduced antibiotic use in animals. For many genes, there was no statistical difference in the prevalence of resistance genes in the intervention group compared to the comparator group. The lack of a statistically significant difference does not necessarily indicate the lack of association between prevalence of resistance genes and interventions, as this may be an issue of insufficient power. Individual studies had small sample sizes overall, with some studies conducting genetic screening only on a subset of isolates. Studies tended to be underpowered to detect differences in the prevalence of resistant genes between groups. Non-statistically significant trends are not represented in the table above.

The majority of studies that screened for resistant genes only in phenotypically resistant isolates showed no difference in the prevalence of resistance genes between intervention and control groups, which was expected. These results are helpful in exploring the presence of resistance genes that drive phenotypic antibiotic resistance, but do not provide information regarding overall prevalence of resistance genes in intervention and control groups. That is, phenotypically resistant isolates would be expected to have genetic resistance elements regardless of whether an intervention that reduced antibiotic use was implemented. We have presented the data from these studies not to show differences in prevalence of resistance between intervention and control groups, but to provide a comprehensive description of genetic evidence in this research area. Studies rarely evaluated genes that were not related to the restricted antibiotic, so the complete effect of any single intervention across a wide range of resistance genes remains unclear.

ix. GRADE tables

An overall assessment of the strength of evidence for the effect of interventions that reduce antibiotic use in food animals on antibiotic resistance in this population was completed using the GRADE framework (Table 15).

Table 15. PICOD 1 GRADE assessment.

Table 15

PICOD 1 GRADE assessment.

Because of the observational nature of studies, the quality rating started at “Low” before any other quality criteria were considered, based on the GRADE framework. There were limitations in risk of bias, particularly with the cross-sectional study designs and minimal adjustment for potential confounders. However, these limitations did not downgrade the quality rating due to the considerable volume of evidence and the consistency of findings across many different layers of stratification (across all bacterial groups, animal species, antibiotic classes, and sample types).

c. Human studies

i. Study characteristics

Twenty-one studies examined antimicrobial resistance in humans (see Table 16 for a summary of study characteristics and Table 17 for detailed characteristics for individual studies).

Table 16. Summary of study characteristics for human studies.

Table 16

Summary of study characteristics for human studies.

Table 17. Summary of the 21 studies examining antibiotic resistance in humans.

Table 17

Summary of the 21 studies examining antibiotic resistance in humans.

The majority of studies (n=12) were in farmers and employees of farms, along with their family members. Six studies examined antibiotic resistance from patient samples provided by laboratories, either in hospital or in outpatient facilities, while five studies were in healthy adults without disease. The most common intervention studied was externally imposed bans or restrictions of antibiotic use in animals (n=9); two studies included organic interventions, five included an antibiotic-free or a similar intervention, and five consisted of voluntary limitations. The most commonly studied bacteria were Staphylococcus spp. and Enterococcus spp. Most studies tested resistance to a single class of antibiotics, specifically to penicillins for Staphylococcus spp. and glycopeptides for Enterococcus spp.

ii. Study quality

Study quality was assessed for all 21 human studies (Tables 18 and 19).

Table 18. Assessment of study quality for individual human studies.

Table 18

Assessment of study quality for individual human studies.

Table 19. Numbers of human studies meeting each study quality criterion.

Table 19

Numbers of human studies meeting each study quality criterion.

The strengths and weaknesses of these studies were similar to the studies that examined antibiotic resistance in animals described previously. They tended to have well-described research objectives and outcome variables. The human studies did tend to have a better description of characteristics of the study sample, compared with animal studies, although only nine of 21 studies met this quality criterion. One of the most significant quality concerns was that study populations tended not to be representative of the general population with over half of studies being in farm workers. Study findings and conclusions that support a reduction of antibiotic resistance in farmers with interventions that reduce antibiotic use in animals may therefore not be generalizable to the general populations. Furthermore, the link between antibiotic use in animals and antibiotic resistance in humans is complex and the causal mechanisms are unclear and likely multi-faceted. Despite this complexity, only four studies were considered to have adequately adjusted for potential confounding variables. Other issues include the lack of information reported in the studies to demonstrate that intervention and control groups were comparable and low sample sizes, with one study including only a total of nine participants (151).

iii. Synthesis of results

There were two main groups of studies within the 21 included human studies: 1) studies examining antibiotic resistance in farmers or those with direct contact with livestock (n=12); and 2) studies examining antibiotic resistance patterns in those without direct contact with livestock animals (n=9). In the second group, the link between antibiotic use in animals and antibiotic resistance in humans was often indirect and implied. That is, authors tended to report antibiotic resistance trends in humans, using surveillance data, before and after a reduction in use or withdrawal of antibiotics in animals. Any changes to these trends were then attributed to changes in antibiotic use in animals, though many other factors may have contributed to these temporal changes and were often not considered. In both groups of studies, most, but not all, studies reported lower antibiotic resistance in the intervention versus the comparator group. Two Danish studies reported an increased prevalence of antibiotic resistance over time in the general human population, despite a restriction of antibiotic use in animals in this country (62, 179).

Few studies examined genetic elements of bacterial antibiotic resistance. In studies of farm workers, genetic data from two studies (51, 184) suggested that antibiotic resistance in bacteria isolated from these workers originated from animals. One study (162) suggested that methicillin-resistant S. aureus (MRSA) was livestock-associated on conventional farms, but that MRSA that was isolated on antibiotic-free farms did not have features of livestock association. This suggests that resistant S. aureus can be found on farms where there is no selective pressure from animal uses of antibiotics because of other non-animal sources of resistance. Only one study in the nine that examined antibiotic resistance trends in non-farm workers commented on the genetic origins of resistance. This study (100) indicated that the genetic and virulence factors of antibiotic resistant E. coli in humans more closely resembled E. coli isolates in animals compared to antibiotic susceptible isolates in humans.

Of the 21 studies that reported antibiotic resistance in humans and its association with interventions that reduced antibiotic use in animals, 13 were able to be meta-analyzed. All 13 studies showed either no difference or a lower risk of antibiotic resistance in the intervention group compared to the control group. Results from nine of the 13 studies were statistically significant, with absolute risk differences ranging from −9% to −85%. The pooled estimate of the absolute risk difference of antibiotic resistance, across all classes of antibiotics, was −0.24 (95% CI −0.42, −0.06). That is, the pooled prevalence of antibiotic resistant bacteria in humans was 24% lower in intervention groups where there was reduced used of antibiotics in animals, compared to control groups (Figure 6).

Figure 6. Pooled absolute risk differences of antibiotic resistance in humans.

Figure 6

Pooled absolute risk differences of antibiotic resistance in humans.

The study by Harper et al. (90) was the only abstract included in the meta-analysis, whereas the other 12 were full-text articles published in peer-reviewed journals. It did also have significant limitations in quality, but whether these limitations were due to restrictions in reporting (as it was a meeting abstract) versus actual limitations in study validity are unclear. We performed a sensitivity analysis, removing the study by Harper et al. from the meta-analysis. This resulted in only a very slight decrease to the pooled absolute risk difference (to −0.21 [95% CI −0.40, −0.03]).

Similar to the animal studies, a high degree of heterogeneity was evident, with an I2 value of 97.4% and a p-value for the Cochran Q test <0.05. Stratified analysis by intervention group, bacterial group, or sample type was not completed due to insufficient numbers of studies.

The conclusions of the remaining eight studies that could not be meta-analyzed are summarized in Table 20.

Table 20. Study synopsis and author conclusions for the 8 human studies for which no meta-analysis could be undertaken.

Table 20

Study synopsis and author conclusions for the 8 human studies for which no meta-analysis could be undertaken.

iv. Stratified analysis by human population

We conducted stratified analysis, based on the human population. That is, meta-analysis was stratified into 1) studies examining antibiotic resistance in farm workers or those with direct contact with livestock animals; and 2) studies examining antibiotic resistance in humans without known direct contact with livestock animals (Figure 7)

Figure 7. Stratified meta-analysis by human population.

Figure 7

Stratified meta-analysis by human population.

Although the pooled effect estimates were statistically significant in both populations, the pooled effect was stronger in farm workers (−0.29 [95% CI −0.54, −0.04]) compared to humans without direct contact with livestock animals (−0.09 [95% CI −0.13, −0.05]). That is, the pooled prevalence of antibiotic resistant bacteria in humans with direct contact to livestock animals was 29% lower when interventions that reduce antibiotic use in the livestock animals were implemented. For humans without direct contact to livestock animals, the pooled prevalence of antibiotic resistant bacteria was 9% lower when interventions that reduce antibiotic use in animals were implemented.

v. Publication bias

A funnel plot was produced, which included the 13 human studies that were meta-analyzed. Visual inspection of the funnel plot did reveal visual asymmetry (Figure 8), and Begg’s test for funnel plot asymmetry was statistically significant (p=0.05).

Figure 8. Funnel plot for human studies included in meta-analysis.

Figure 8

Funnel plot for human studies included in meta-analysis.

Sensitivity analysis using the trim and fill method was performed. There was no change in the risk reduction of antibiotic resistance in humans with interventions that reduced antibiotic use in animals with (−0.27 [95% CI −0.43, −0.10]) and without (−0.24 [95% −0.42, −0.06]) imputation, suggesting that publication bias, if present, likely had minimal effect on our findings. Similar to the animal studies, known clinical heterogeneity, including heterogeneity in human populations studied, bacteria studied, and countries of origin, may have also contributed to the funnel plot asymmetry. The asymmetry therefore may not be solely attributable to publication bias.

vi. GRADE tables

An overall assessment of the strength of evidence for the effect of interventions that reduce antibiotic use in food animals on antibiotic resistance in humans was completed using the GRADE framework (Table 21).

Table 21. PICOD 2 GRADE assessment.

Table 21

PICOD 2 GRADE assessment.

Because of the observational nature of studies, the quality rating started at “Low” before any other quality criteria were considered. There was direct evidence that reduction in antibiotic use in food animals was associated with a 29% reduction in antibiotic resistance in humans who have direct contact with these animals. Although the mechanisms are unclear and the evidence is more indirect, a 9% reduction in antibiotic resistance for human populations without direct contact with food animals was still demonstrated, suggesting that the benefit of interventions that reduce antibiotic use in animals may extend broadly. There were limitations in risk of bias, particularly with the observational study designs and minimal adjustment for potential confounders. These limitations did not further downgrade the quality rating due to the consistency of findings across different bacterial groups, animal species, antibiotic classes, and sample types, and because of the similarity of findings when considering animal data (PICOD 1).

Discussion

In this systematic review of 181 studies, an association was found between interventions that restrict antibiotic use and reduction in prevalence of antibiotic resistant bacteria in animals and animal products and also in the human population. When considering only the studies that examined antibiotic resistance in food animals, this association was consistent across all the studied bacterial groups, animal populations, and sample types, although the association appeared to be weaker for Campylobacter species. In addition, all interventions that reduced the use of antibiotics, whether the reduction was voluntary or government-imposed, and whether it included complete withdrawal of all antibiotics or limitation of use of only certain antibiotics for certain indications, seemed to be effective in reducing antibiotic resistance in animals. The magnitude of effect depended upon the antibiotic class studied, baseline antibiotic resistance, sample types, and bacterial species. Overall, reducing antibiotic use decreased prevalence of antibiotic resistant bacteria by about 15% and decreased prevalence of multi-drug resistant bacteria by between 24–32%. Furthermore, with some evidence in the literature suggesting that a ban of antibiotic growth-promoters may result in increased use of therapeutic antibiotics in animals (211), it is reassuring that our meta-analysis did not reveal any evidence of increased resistance to antibiotics with such interventions.

The evidence for reduction in prevalence of antibiotic resistant bacteria in humans as a result of reduced antibiotic use in food animals was more limited and less robust than for the reduction of antibiotic resistance in the animals themselves. Meta-analysis of 13 of the 21 human resistance studies showed similar results to the meta-analyses of the animal studies. Interventions to reduce antibiotic use in animals were associated with a 24% absolute reduction in the prevalence of antibiotic resistant bacteria in humans. With nine of the 13 meta-analyzed studies being in farm workers and their direct contacts, generalizability of the findings to the general population may be limited. However, our stratified meta-analysis did suggest that reduction in antibiotic resistance in humans may extend beyond just farm workers, although the effect appears weaker for those without direct contact with animals.

Three recent systematic reviews have explored antibiotic resistance in bacteria isolated from organically—versus conventionally—farmed food animals (212214). Their conclusions were similar to the ones we have reached, although all focused only on the single type of intervention. In addition, the review by Young et al. (214) included studies that examined resistance in Campylobacter species only, while the review by Wilhelm et al. included studies that tested dairy products only (213). Our systematic review is, to our knowledge, the first to include studies that examine all types of interventions that aim to reduce antibiotic use in animals, with no limitation on the type of sample collected, the animal species included, or the bacterial species tested. Therefore, this is by far the most comprehensive review on this topic. We also believe that this is the first systematic review of studies examining the association between interventions to reduce antibiotic use in food animals and changes to antibiotic resistance in bacteria in humans. Given that a key consideration for restricting antibiotic use in food animals is its potential to decrease the level of antibiotic resistance in zoonotic bacteria, this summary of evidence was commissioned by WHO to inform the development of policy recommendations for public health.

The question posed by the WHO regarding the effect on antibiotic resistance in humans, when interventions to reduce antibiotic use in food animals are undertaken, is complex. Because of the many considerations in cross-species transmission of resistant bacteria and their genetic elements, this research question cannot be easily studied and any interpretations of research findings will require a host of assumptions and inferences. There is biologic plausibility that interventions to reduce antibiotic use in food animals may reduce antibiotic resistance in humans. The results of the meta-analysis undertaken on the human studies included in our systematic review consistently suggest that antibiotic resistant bacteria can be exchanged between livestock and farm workers. It is plausible that antibiotic resistant bacteria can also be exchanged between animals and the general population; however, the evidence for this is weaker and less consistent and more indirect in the studies included in our systematic review. Transmission from food animals to the human population can occur through contaminated animal retail products (215), although the risk of this may be low if animal products are adequately prepared and cooked. Resistance can also be transmitted through the environment through animal faecal matter, wastewater, and contaminated produce (216).

Further adding to the complexity of the issue of antibiotic resistance is that a number of different biological drivers are involved in the selection and persistence of antibiotic resistance genes both in the natural environment and in the presence of antibiotic use (17). That is, development and persistence of resistance does not depend solely on the use of antibiotics, as it can evolve naturally in bacterial populations and may provide survival benefits for bacteria in the absence of antibiotic selection pressure. With these caveats in mind, our systematic review has shown that reducing the level of antibiotic resistance in livestock populations is likely a beneficial strategy for animals and humans. Though we do not fully understand the selection and mechanisms of cross-species transmission of resistant bacteria and their genetic elements, it seems clear that the health of humans, animals, and the ecosystem are intricately linked. In this regard it is evident that a One Health approach will be required to address the problem of antimicrobial resistance (217). Many jurisdictions have recognized this and have therefore implemented comprehensive surveillance of antimicrobial resistance in both the human and animal population and better co-ordination between public health and veterinary antimicrobial resistance reporting systems (218220). These tracking systems have the potential to provide high-quality information, such as detailed genomic data, necessary to track resistant bacteria in diverse settings, to better understand the links between antibiotic resistance in animals and in humans (221).

There are some caveats and limitations to our systematic review and meta-analyses. Despite considerable heterogeneity across both food animal and human sets of studies, we chose to pool results through meta-analyses. This is partially because we anticipated a priori that there would be heterogeneity across studies, given the wide variety of settings studied and interventions described and tested. Anticipating this, we used random effect models in all of our analyses and conducted stratified analyses to explore contributors to heterogeneity. In the animal studies (PICOD 1), meta-analyses were conducted separately for groups that could not be combined in a biologically sensible way. For example, we did not pool antibiotic resistance results for all bacterial groups as their origins, resistance patterns, and isolation techniques differ widely. The bacterial species were therefore analyzed within four distinct and biologically similar groups. Even with stratification in our meta-analytic approach, there remained significant heterogeneity as demonstrated by Cochran Q test results and high I2 values. Despite this heterogeneity, the conclusions from the meta-analyses were remarkably consistent regardless of the bacteria studied, the antibiotic class to which resistance was tested, or the sample type. Further stratification by intervention type had no effect on these associations, highlighting the robustness of these conclusions. We conducted meta-analysis on human studies (PICOD 2) without any stratification by bacterial or sample type given the low number of studies in each category. We recognized the heterogeneity of these studies, but given the consistency of findings in the series of meta-analyses that were undertaken for the animal studies, there did not appear to be significant effect modification by intervention type, antibiotic tested, or sample tested that would be a contraindication to meta-analysis.

As with any systematic review, our study is limited by the varied quality and nature of the underlying studies. While studies had clear strengths in reporting their objectives, hypotheses, and outcomes clearly, areas of deficiency included lack of description of study groups, lack of description of interventions, lack of a control group for longitudinal studies, and inadequate adjustment for potential confounders. The large majority of studies were observational, and therefore could not prove causality between reduction in antibiotic use and reduction in the prevalence of antibiotic resistant bacteria. The issue of causality was especially problematic for human studies as noted above, where linkages between bacterial resistance in food animals and bacterial resistance in humans were indirect and implied. Lastly, the majority of studies were from North America and Europe, while only one study originated from India, China, or Brazil—three of the top five global users of antibiotics in livestock and in humans (222). This likely reflects the geographic areas where there has been greatest and least focus, respectively, on the reduction of antibiotic use in animals and may limit the generalizability of our findings. Furthermore, the majority of the included studies had a cross-sectional design, limiting causal inferences of associations between interventions and the reduction in antibiotic use.

The body of literature that we have identified in the systematic review has definite limitations. As noted above, these include limitations in study designs and quality and the issues of making causal inferences in this very complex area. However, we also note a substantial body of evidence that strongly suggests reduction of the prevalence of antibiotic resistant bacteria in food animals when antibiotic use is reduced in this population, and the smaller, albeit not insignificant body of evidence suggesting that such interventions may also reduce the prevalence of antibiotic resistant bacteria in humans (particularly those with direct contact with food animals). This evidence is not only substantial in its volume, but also in its consistency. The findings held regardless of bacteria studied, food animals in question, interventions implemented, samples studied, and regardless of the quality of the studies. They held when considering phenotypic resistance and genotypic resistance. The mechanisms may be indirect when considering transmission from humans to animals, but are biologically plausible. Therefore, despite the limitations posed by the quality of studies and the methodological issues and assumptions that are made in them, it would be imprudent to entirely discount this body of evidence given its coherence and consistency.

As human and veterinary medicine public health researchers, our mandate in this WHO-commissioned work has been the summarization and presentation of the evidence on the relationship between various antibiotic reduction interventions and antibiotic resistance patterns. Our findings reveal that there is a large body of evidence suggesting that interventions that restrict antibiotic use in food animals is associated with reduction in antibiotic resistance in these animals, and a smaller body of evidence showing a similar effect in humans. Decision-makers will need to determine whether these findings are sufficient to recommend widespread antibiotic reduction interventions.

References

1.
World Health Organization. Agreement for Performance of Work Between the WHO Department of OHE/FOS/FZD and University of Calgary. Geneva, Switzerland. 2016.
2.
World Health Organization. Joint FAO/OIE/WHO expert workshop on non-human antimicrobial usage and antimicrobial resistance: Scientific asssessment. Geneva, Switzerland. 1–5 December 2003.
3.
World Health Organization. Antimicrobial use in aquaculture and antimicrobial resistance. Report of a joint FAO/OIE/WHO expert consultation on antimicrobial use in aquaculture and antimicrobial resistance. Seoul, Republic of Korea. 13–16 June 2006.
4.
Tusevljak N, Dutil L, Rajic A, Uhland FC, McClure C, St-Hilaire S, et al. Antimicrobial use and resistance in aquaculture: findings of a globally administered survey of aquaculture-allied professionals. Zoonoses Public Health. 2013;60(6):426–36. [PubMed: 23072270]
5.
. Antibiotic resistance: An ecological perspective on an old problem. Washington, DC: American Academy of Microbiology; 2009. [PubMed: 32644325]
6.
Bauer-Garland J, Frye JG, Gray JT, Berrang ME, Harrison MA, Fedorka-Cray PJ. Transmission of Salmonella enterica serotype Typhimurium in poultry with and without antimicrobial selective pressure. Journal of Applied Microbiology. 2006;101(6):1301–8. [PubMed: 17105560]
7.
Looft T, Johnson TA, Allen HK, Bayles DO, Alt DP, Stedtfeld RD, et al. In-feed antibiotic effects on the swine intestinal microbiome. Proc Natl Acad Sci U S A. 2012;109(5):1691–6. [PMC free article: PMC3277147] [PubMed: 22307632]
8.
Young I, Rajic A, Wilhelm BJ, Waddell L, Parker S, McEwen SA. Comparison of the prevalence of bacterial enteropathogens, potentially zoonotic bacteria and bacterial resistance to antimicrobials in organic and conventional poultry, swine and beef production: a systematic review and meta-analysis. Epidemiol Infect. 2009;137(9):1217–32. [PubMed: 19379542]
9.
World Health Organization. Global principles for the containment of antimicrobial resistance in animals intended for food: Report of a WHO consultation with the participation of the Food and Agriculture Organization of the United Nations and the Office International des Epizooties. Geneva, Switzerland. 5–9 June 2000.
10.
World Health Organization. Critically important antibacterial agents for human medicine for risk management strategies of non-human use: Report of a WHO working group consultation. Canberra, Australia. 15–18 February 2005.
11.
Canadian Integrated CIPARS. Program for Antimicrobial Resistance Surveillance (CIPARS) 2016 [Available from: http://www​.phac-aspc​.gc.ca/cipars-picra/index-eng.php.
12.
DANMAP. Danish programme for surveillance of antimicrobial consumption and resistance in bacteria from animals, food and humans 2016 [
13.
World Health Organization. Global Antimicrobial Resistance Surveillance System: Manual for Early Implementation 2016 [Available from: http://www​.who.int/antimicrobial-resistance​/publications/surveillance-system-manual/en/.
14.
United States Department of Agriculture. Antimicrobial Resistance Overview (AMR) 2016 [Available from: http://www​.usda.gov/wps​/portal/usda/usdahome?contentidonly​=true&contentid=antimicrobial.html.
15.
Aarestrup FM, Seyfarth AM, Emborg HD, Pedersen K, Hendriksen RS, Bager F. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob Agents Chemother. 2001;45(7):2054–9. [PMC free article: PMC90599] [PubMed: 11408222]
16.
World Health Organization. Critically important antimicrobials for human medicine: 1st revision. 2007.
17.
Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiology and molecular biology reviews : MMBR. 2010;74(3):417–33. [PMC free article: PMC2937522] [PubMed: 20805405]
18.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9, W64. [PubMed: 19622511]
19.
WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR). Critically Important Antimicrobials for Human Medicine. 2011.
20.
World Organisation for Animal Health (OIE). OIE list of antimicrobial agents of veterinary importance. 2015.
21.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of epidemiology and community health. 1998;52(6):377–84. [PMC free article: PMC1756728] [PubMed: 9764259]
22.
DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary clinical trials. 2007;28(2):105–14. [PubMed: 16807131]
23.
Borenstein M, Hedges L, Higgins JP, Rothstein HR. Introduction to Meta-Analysis. Chichester, UK: John Wiley & Sons, Ltd; 2009.
24.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539–58. [PubMed: 12111919]
25.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal. 2003;327(7414):557–60. [PMC free article: PMC192859] [PubMed: 12958120]
26.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101. [PubMed: 7786990]
27.
Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–63. [PubMed: 10877304]
28.
Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. Bmj. 2016;353:i2016. [PubMed: 27353417]
29.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology. 2011;64(4):383–94. [PubMed: 21195583]
30.
World Health Organization. Highest Priority Critically Important Antimicrobials 2016 [Available from: http://www​.who.int/foodsafety/cia/en/.
31.
Aarestrup FM. Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. Microb Drug Resist. 1995;1(3):255–7. [PubMed: 9158784]
32.
Aarestrup FM, Bager F, Andersen JS. Association between the use of avilamycin for growth promotion and the occurrence of resistance among Enterococcus faecium from broilers: epidemiological study and changes over time. Microb Drug Resist. 2000;6(1):71–5. [PubMed: 10868810]
33.
Aarestrup FM, Hasman H, Jensen LB, Moreno M, Herrero IA, Dominguez L, et al. Antimicrobial resistance among enterococci from pigs in three European countries. Appl Environ Microbiol. 2002;68(8):4127–9. [PMC free article: PMC124043] [PubMed: 12147518]
34.
Aarestrup FM, Kruse H, Tast E, Hammerum AM, Jensen LB. Associations between the use of antimicrobial agents for growth promotion and the occurrence of resistance among Enterococcus faecium from broilers and pigs in Denmark, Finland, and Norway. Microb Drug Resist. 2000;6(1):63–70. [PubMed: 10868809]
35.
Abdalrahman LS, Stanley A, Wells H, Fakhr MK. Isolation, Virulence, and Antimicrobial Resistance of Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin Sensitive Staphylococcus aureus (MSSA) Strains from Oklahoma Retail Poultry Meats. Int J Environ Res Public Health. 2015;12(6):6148–61. [PMC free article: PMC4483693] [PubMed: 26035662]
36.
Agerso Y, Aarestrup FM. Voluntary ban on cephalosporin use in Danish pig production has effectively reduced extended-spectrum cephalosporinase-producing Escherichia coli in slaughter pigs. Journal of Antimicrobial Chemotherapy. 2013;68(3):569–72. [PubMed: 23129728]
37.
Agga GE, Schmidt JW, Arthur TM, editors. Antimicrobial resistance of enteric bacteria among ceftiofur treated and non-antimicrobial treated co-mingled pasture beef cows. 4th ASM Conference on Antimicrobial resistance in zoonotic bacteria and foodborne pathogens; 2015 8–11 May 2015; Washington, United States.
38.
Alali WQ, Thakur S, Berghaus RD, Martin MP, Gebreyes WA. Prevalence and distribution of Salmonella in organic and conventional broiler poultry farms. Foodborne Pathog Dis. 2010;7(11):1363–71. [PubMed: 20617937]
39.
Alvarez-Fernandez E, Cancelo A, Diaz-Vega C, Capita R, Alonso-Calleja C. Antimicrobial resistance in E. coli isolates from conventionally and organically reared poultry: A comparison of agar disc diffusion and Sensi Test Gram-negative methods. Food Control. 2013;30(1):227–34.
40.
Alvarez-Fernandez E, Dominguez-Rodriguez J, Capita R, Alonso-Calleja C. Influence of housing systems on microbial load and antimicrobial resistance patterns of Escherichia coli isolates from eggs produced for human consumption. Journal of Food Protection. 2012;75(5):847–53. [PubMed: 22564932]
41.
Avrain L, Humbert F, L’Hospitalier R, Sanders P, Vernozy-Rozand C, Kempf I. Antimicrobial resistance in Campylobacter from broilers: association with production type and antimicrobial use. Vet Microbiol. 2003;96(3):267–76. [PubMed: 14559174]
42.
Bager F, Aarestrup FM, Madsen M, Wegener HC. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin. Microbial Drug Resistance. 1999;5(1):53–6. [PubMed: 10332722]
43.
Barlow RS, Fegan N, Gobius KS. A comparison of antibiotic resistance integrons in cattle from separate beef meat production systems at slaughter. Journal of Applied Microbiology. 2008;104(3):651–8. [PubMed: 17927756]
44.
Barlow RS, Fegan N, Gobius KS. Integron-containing bacteria in faeces of cattle from different production systems at slaughter. Journal of Applied Microbiology. 2009;107(2):540–5. [PubMed: 19302491]
45.
Bauer-Garland J, Frye JG, Gray JT, Berrang ME, Harrison MA, Fedorka-Cray PJ. Transmission of Salmonella enterica serotype Typhimurium in poultry with and without antimicrobial selective pressure. Journal of Applied Microbiology. 2006;101(6):1301–8. [PubMed: 17105560]
46.
Bengtsson B, Wierup M. Antimicrobial resistance in Scandinavia after ban of antimicrobial growth promoters. Animal Biotechnology. 2006;17(2):147–56. [PubMed: 17127526]
47.
Bennedsgaard TW, Thamsborg SM, Aarestrup FM, Enevoldsen C, Vaarst M, Christoffersen AB. Resistance to penicillin of Staphylococcus aureus isolates from cows with high somatic cell counts in organic and conventional dairy herds in Denmark. Acta Vet Scand. 2006;48:24. [PMC free article: PMC1687190] [PubMed: 17125515]
48.
Boerlin P, Wissing A, Aarestrup FM, Frey J, Nicolet J. Antimicrobial growth promoter ban and resistance to macrolides and vancomycin in enterococci from pigs. J Clin Microbiol. 2001;39(11):4193–5. [PMC free article: PMC88516] [PubMed: 11682559]
49.
Bombyk RA, Bykowski AL, Draper CE, Savelkoul EJ, Sullivan LR, Wyckoff TJ. Comparison of types and antimicrobial susceptibility of Staphylococcus from conventional and organic dairies in west-central Minnesota, USA. Journal of Applied Microbiology. 2008;104(6):1726–31. [PubMed: 18179539]
50.
Bombyk RAM, Helland TJ, Wyckoff TJO. Characterization of tetracycline resistance determinants in Staphylococcus from conventional and organic dairy cows in west-central Minnesota. Abstracts of the General Meeting of the American Society for Microbiology. 2007;107:744.
51.
Borgen K, Simonsen GS, Sundsfjord A, Wasteson Y, Olsvik O, Kruse H. Continuing high prevalence of VanA-type vancomycin-resistant enterococci on Norwegian poultry farms three years after avoparcin was banned. Journal of Applied Microbiology. 2000;89(3):478–85. [PubMed: 11021580]
52.
Borgen K, Sørum M, Wasteson Y, Kruse H. VanA-type vancomycin-resistant enterococci (VRE) remain prevalent in poultry carcasses 3 years after avoparcin was banned. Int J Food Microbiol. 2001;64(1–2):89–94. [PubMed: 11252515]
53.
Boutet P, Detilleux J, Motkin M, Deliege M, Piraux E, Depinois A, et al. A comparison of somatic cell count and antimicrobial susceptibility of subclinical mastitis pathogens in organic and conventional dairy herds./Comparaison du taux cellulaire et de la sensibilité antimicrobienne des germes responsables de mammite subclinique bovine entre les filières conventionnelle et biologique. Annales de Médecine Vétérinaire. 2005;149(3):173–82.
54.
Boyer TC. Antibiotic resistance in the lower intestinal microbiota of dairy cattle: Longitudinal analysis of phenotypic and genotypic resistance [Ph.D.]. Ann Arbor: University of Minnesota; 2012.
55.
Bunner CA, Norby B, Bartlett PC, Erskine RJ, Downes FP, Kaneene JB. Prevalence and pattern of antimicrobial susceptibility in Escherichia coli isolated from pigs reared under antimicrobial-free and conventional production methods. J Am Vet Med Assoc. 2007;231(2):275–83. [PubMed: 17630898]
56.
Buntenkoetter V, Blaha T, Tegeler R, Fetsch A, Hartmann M, Kreienbrock L, et al. Comparison of the phenotypic antimicrobial resistances and spa-types of methicillin-resistant Staphylococcus aureus (MRSA) isolates derived from pigs in conventional and in organic husbandry systems. Berl Munch Tierarztl Wochenschr. 2014;127(3–4):135–43. [PubMed: 24693659]
57.
Butaye P, Devriese LA, Goossens H, Ieven M, Haesebrouck F. Enterococci with acquired vancomycin resistance in pigs and chickens of different age groups. Antimicrobial Agents and Chemotherapy. 1999;43(2):365–66. [PMC free article: PMC89079] [PubMed: 9925534]
58.
Government of Canada. Reductions in Antimicrobial Use and Resistance: Preliminary Evidence of the Effect of the Canadian Chicken Industry’s Elimination of Use of Antimicrobials of Very High Importance to Human Medicine. Government of Canada; 2016. p. 1–5.
59.
Cho S, Bender JB, Diez-Gonzalez F, Fossler CP, Hedberg CW, Kaneene JB, et al. Prevalence and characterization of Escherichia coli O157 isolates from Minnesota dairy farms and county fairs. Journal of Food Protection. 2006;69(2):252–9. [PubMed: 16496562]
60.
Cho S, Fossler CP, Diez-Gonzalez F, Wells SJ, Hedberg CW, Kaneene JB, et al. Antimicrobial susceptibility of Shiga toxin-producing Escherichia coli isolated from organic dairy farms, conventional dairy farms, and county fairs in Minnesota. Foodborne Pathog Dis. 2007;4(2):178–86. [PubMed: 17600485]
61.
Cicconi-Hogan KM, Belomestnykh N, Gamroth M, Ruegg PL, Tikofsky L, Schukken YH. Prevalence of methicillin resistance in coagulase-negative staphylococci and Staphylococcus aureus isolated from bulk milk on organic and conventional dairy farms in the United States. Journal of Dairy Science. 2014;97(5):2959–64. [PubMed: 24582450]
62.
Coalition for Animal Health. Political Bans on Antibiotics are Counterproductive. European Test Case: Increased Animal Disease, Mixed Human Health Benefit. nd.
63.
Cohen Stuart J, van den Munckhof T, Voets G, Scharringa J, Fluit A, Hall ML. Comparison of ESBL contamination in organic and conventional retail chicken meat. Int J Food Microbiol. 2012;154(3):212–4. [PubMed: 22260927]
64.
Cui S. Detection and characterization of Escherichia coli O157:H7 and Salmonella in food [Ph.D.]. Ann Arbor: University of Maryland, College Park; 2004.
65.
Cui S, Ge B, Zheng J, Meng J. Prevalence and antimicrobial resistance of Campylobacter spp. and Salmonella serovars in organic chickens from Maryland retail stores. Appl Environ Microbiol. 2005;71(7):4108–11. [PMC free article: PMC1169031] [PubMed: 16000828]
66.
Cuny C, Friedrich AW, Witte W. Absence of Livestock-Associated Methicillin-Resistant Staphylococcus aureus Clonal Complex CC398 as a Nasal Colonizer of Pigs Raised in an Alternative System. Applied and Environmental Microbiology. 2012;78(4):1296–7. [PMC free article: PMC3273000] [PubMed: 22156420]
67.
Del Grosso M, Caprioli A, Chinzari P, Fontana MC, Pezzotti G, Manfrin A, et al. Detection and Characterization of Vancomycin-Resistant Enterococci in Farm Animals and Raw Meat Products in Italy. Microbial Drug Resistance. 2000;6(4):313–8. [PubMed: 11272260]
68.
Desmonts MH, Dufour-Gesbert F, Avrain L, Kempf I. Antimicrobial resistance in Campylobacter strains isolated from French broilers before and after antimicrobial growth promoter bans. Journal of antimicrobial chemotherapy. 2004;54(6):1025–30. [PubMed: 15537699]
69.
Docic M, Bilkei G. Differences in antibiotic resistance in Escherichia coli, isolated from East-European swine herds with or without prophylactic use of antibiotics. J Vet Med B Infect Dis Vet Public Health. 2003;50(1):27–30. [PubMed: 12710497]
70.
Dolejska M, Jurcickova Z, Literak I, Pokludova L, Bures J, Hera A, et al. IncN plasmids carrying bla CTX-M-1 in Escherichia coli isolates on a dairy farm. Vet Microbiol. 2011;149(3–4):513–6. [PubMed: 21276666]
71.
Dorado-García A, Bos ME, Dohmen W, Verstappen KM, Wagenaar JA, Heederik DJ, editors. Intervention Measures Reducing Livestock-Associated MRSA on Pig Farms in The Netherlands: A Longitudinal Study. 3rd ASM-ESCMID Conference on Methicillin-resistant Staphylococci in Animals: Veterinary and Public Health Implications; 2013; Copenhagen, Denmark.
72.
Dorado-Garcia A, Dohmen W, Bos ME, Verstappen KM, Houben M, Wagenaar JA, et al. Dose-response relationship between antimicrobial drugs and livestock-associated MRSA in pig farming. Emerg Infect Dis. 2015;21(6):950–9. [PMC free article: PMC4451891] [PubMed: 25989456]
73.
Dorado-Garcia A, Graveland H, Bos ME, Verstappen KM, Van Cleef BA, Kluytmans JA, et al. Effects of Reducing Antimicrobial Use and Applying a Cleaning and Disinfection Program in Veal Calf Farming: Experiences from an Intervention Study to Control Livestock-Associated MRSA.[Erratum appears in PLoS One. 2015;10(9):e0139536; PMID: 26413843]. PLoS ONE. 2015;10(8):e0135826. [PMC free article: PMC4549302] [PubMed: 26305895]
74.
Dutil L, Irwin R, Finley R, Ng LK, Avery B, Boerlin P, et al. Ceftiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans, Canada. Emerg Infect Dis. 2010;16(1):48–54. [PMC free article: PMC2874360] [PubMed: 20031042]
75.
El-Shibiny A, Connerton PL, Connerton IF. Enumeration and diversity of campylobacters and bacteriophages isolated during the rearing cycles of free-range and organic chickens. Appl Environ Microbiol. 2005;71(3):1259–66. [PMC free article: PMC1065130] [PubMed: 15746327]
76.
Emborg HD, Andersen JS, Seyfarth AM, Andersen SR, Boel J, Wegener HC. Relations between the occurrence of resistance to antimicrobial growth promoters among Enterococcus faecium isolated from broilers and broiler meat. Int J Food Microbiol. 2003;84(3):273–84. [PubMed: 12810291]
77.
Fraqueza MJ, Martins A, Borges AC, Fernandes MH, Fernandes MJ, Vaz Y, et al. Antimicrobial resistance among Campylobacter spp. strains isolated from different poultry production systems at slaughterhouse level. Poultry Science. 2014;93(6):1578–86. [PubMed: 24879708]
78.
Gallay A, Prouzet-Mauleon V, Kempf I, Lehours P, Labadi L, Camou C, et al. Campylobacter antimicrobial drug resistance among humans, broiler chickens, and pigs, France. Emerg Infect Dis. 2007;13(2):259–66. [PMC free article: PMC2725848] [PubMed: 17479889]
79.
Garcia-Migura L, Pleydell E, Barnes S, Davies RH, Liebana E. Characterization of vancomycin-resistant Enterococcus faecium isolates from broiler poultry and pig farms in England and Wales. J Clin Microbiol. 2005;43(7):3283–9. [PMC free article: PMC1169128] [PubMed: 16000449]
80.
Garmo RT, Waage S, Sviland S, Henriksen BI, Osteras O, Reksen O. Reproductive performance, udder health, and antibiotic resistance in mastitis bacteria isolated from Norwegian Red cows in conventional and organic farming. Acta Vet Scand. 2010;52:11. [PMC free article: PMC2829576] [PubMed: 20141638]
81.
Ge B, Zheng J, Meng J, editors. Antimicrobial susceptibility of Campylobacter from retail organic and conventional chickens. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct–Nov.
82.
Gebreyes WA, Thakur S, Morrow WEM. Comparison of Prevalence, Antimicrobial Resistance, and Occurrence of Multidrug-Resistant Salmonella in Antimicrobial-Free and Conventional Pig Production. Journal of Food Protection. 2006;69(4):743–8. [PubMed: 16629014]
83.
Gellin G, Langlois BE, Dawson KA, Aaron DK. Antibiotic resistance of gram-negative enteric bacteria from pigs in three herds with different histories of antibiotic exposure. Applied and Environmental Microbiology 1989;55(9). [PMC free article: PMC203070] [PubMed: 2802608]
84.
Gerzova L, Babak V, Sedlar K, Faldynova M, Videnska P, Cejkova D, et al. Characterization of antibiotic resistance gene abundance and microbiota composition in feces of organic and conventional pigs from four EU countries. PLoS ONE. 2015;10(7):e0132892-e. [PMC free article: PMC4517930] [PubMed: 26218075]
85.
Guarddon M, Miranda JM, Rodríguez JA, Vázquez BI, Cepeda A, Franco CM. Quantitative detection of tetracycline-resistant microorganisms in conventional and organic beef, pork and chicken meat. CyTA - Journal of Food. 2014;12(4):383–8.
86.
Halbert LW, Kaneene JB, Linz J, Mansfield LS, Wilson D, Ruegg PL, et al. Genetic mechanisms contributing to reduced tetracycline susceptibility of Campylobacter isolated from organic and conventional dairy farms in the midwestern and northeastern United States. Journal of Food Protection. 2006;69(3):482–8. [PubMed: 16541675]
87.
Halbert LW, Kaneene JB, Ruegg PL, Warnick LD, Wells SJ, Mansfield LS, et al. Evaluation of antimicrobial susceptibility patterns in Campylobacter spp isolated from dairy cattle and farms managed organically and conventionally in the midwestern and northeastern United States. J Am Vet Med Assoc. 2006;228(7):1074–81. [PubMed: 16579787]
88.
Hammerum AM, Heuer OE, Emborg HD, Bagger-Skjot L, Jensen VF, Rogues AM, et al. Danish integrated antimicrobial resistance monitoring and research program. Emerg Infect Dis. 2007;13(11):1632–9. [PMC free article: PMC3375779] [PubMed: 18217544]
89.
Han F, Lestari SI, Pu S, Ge B. Prevalence and antimicrobial resistance among Campylobacter spp. in Louisiana retail chickens after the enrofloxacin ban. Foodborne Pathog Dis. 2009;6(2):163–71. [PubMed: 19099357]
90.
Harper AL, Male AJ, Scheibel RP, Hanson BM, Wardyn SE, Smith TC, editors. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in organic and confinement swine operations in the Midwestern United States. ESCMID/ASM Conference; 2009; London, UK.
91.
Harvey R, Funk J, Wittum TE, Hoet AE. A metagenomic approach for determining prevalence of tetracycline resistance genes in the fecal flora of conventionally raised feedlot steers and feedlot steers raised without antimicrobials. American Journal of Veterinary Research. 2009;70(2):198–202. [PubMed: 19231951]
92.
Hässig M, Eugster S, Lewis FI. Herd level antimicrobial resistance in beef calves in Switzerland 1986 through 2011. Open Journal of Veterinary Medicine. 2014;4(11):247–54.
93.
Heuer OE, Pedersen K, Andersen JS, Madsen M. Prevalence and antimicrobial susceptibility of thermophilic Campylobacter in organic and conventional broiler flocks. Lett Appl Microbiol. 2001;33(4):269–74. [PubMed: 11559399]
94.
Heuer OE, Pedersen K, Andersen JS, Madsen M. Vancomycin-resistant enterococci (VRE) in broiler flocks 5 years after the avoparcin ban. Microb Drug Resist. 2002;8(2):133–8. [PubMed: 12118518]
95.
Hiki M, Kawanishi M, Abo H, Kojima A, Koike R, Hamamoto S, et al. Decreased Resistance to Broad-Spectrum Cephalosporin in Escherichia coli from Healthy Broilers at Farms in Japan After Voluntary Withdrawal of Ceftiofur. Foodborne Pathog Dis. 2015;12(7):639–43. [PubMed: 26135895]
96.
Hiroi M, Matsui S, Kubo R, Iida N, Noda Y, Kanda T, et al. Factors for Occurrence of Extended-Spectrum beta-Lactamase-Producing Escherichia coli in Broilers. J Vet Med Sci. 2012;74(12):1635–7. [PubMed: 22786468]
97.
Hoogenboom LA, Bokhorst JG, Northolt MD, van de Vijver LP, Broex NJ, Mevius DJ, et al. Contaminants and microorganisms in Dutch organic food products: a comparison with conventional products. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008;25(10):1195–207. [PubMed: 18608495]
98.
Huijbers PM, van Hoek AH, Graat EA, Haenen AP, Florijn A, Hengeveld PD, et al. Methicillin-resistant Staphylococcus aureus and extended-spectrum and AmpC beta-lactamase-producing Escherichia coli in broilers and in people living and/or working on organic broiler farms. Vet Microbiol. 2015;176(1–2):120–5. [PubMed: 25582613]
99.
Jensen HH, Hayes DJ. Impact of Denmark’s ban on antimicrobials for growth promotion. Current Opinion in Microbiology. 2014;19:30–6. [PubMed: 24997397]
100.
Johnson JR, Sannes MR, Croy C, Johnston B, Clabots C, Kuskowski MA, et al. Antimicrobial drug-resistant Escherichia coli from humans and poultry products, Minnesota and Wisconsin, 2002–2004. Emerg Infect Dis. 2007;13(6):838–46. [PMC free article: PMC2792839] [PubMed: 17553221]
101.
Johnston JR. A comparison of antibiotic resistance in bacteria isolated from conventionally versus organically raised livestock. BIOS (Ocean Grove). 2002;73(2):47–51.
102.
Joseph S, Sapkota A, Cullen P, Wagner D, Hulet M, Hayer J, et al. Reduced resistance to antibiotics among Salmonella spp. recovered from U.S. organic poultry farms. Antimicrobial resistance in zoonotic bacteria and foodborne pathogens in animals, humans and the environment: American Society for Microbiology; 2008. p. 17.
103.
Joseph SW, Paramadhas R, Cullen P, Wagner D, Hulet M, Hayes J, et al. Reduced Resistance to Antibiotics among Enterococcus faecium of Organic Poultry Farm Origin. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2007;47:95–6.
104.
Keelara Veerappa S. Molecular Epidemiology of Salmonella Isolated from Pigs Reared in Distinct Swine Production Systems and Humans [Ph.D.]. Ann Arbor: North Carolina State University; 2013.
105.
Kerouanton A, Rose V, Chidaine B, Kempf I, Denis M. Comparison of organic and conventional pig productions on prevalence, antibiotic resistance and genetic diversity of Escherichia coli [Conference poster]./Résistance à la tétracycline et diversité génétique d’Escherichia coli isolés de porcs biologiques et de porcs conventionnels. Journées de la Recherche Porcine en France. 2014;46:179–80.
106.
Khachatryan AR, Besser TE, Hancock DD, Call DR. Use of a Nonmedicated Dietary Supplement Correlates with Increased Prevalence of Streptomycin-Sulfa-Tetracycline-Resistant Escherichia coli on a Dairy Farm. Applied and Environmental Microbiology. 2006;72(7):4583–8. [PMC free article: PMC1489318] [PubMed: 16820447]
107.
Kieke AL, Borchardt MA, Kieke BA, Spencer SK, Vandermause MF, Smith KE, et al. Use of Streptogramin Growth Promoters in Poultry and Isolation of Streptogramin-Resistant Enterococcus faecium from Humans. The Journal of Infectious Diseases. 2006;194(9):1200–8. [PubMed: 17041845]
108.
Kilonzo-Nthenge A, Brown A, Nahashon SN, Long D. Occurrence and antimicrobial resistance of enterococci isolated from organic and conventional retail chicken. Journal of Food Protection. 2015;78(4):760–6. [PubMed: 25836402]
109.
Klare I, Badstübner D, Konstabel C, Böhme G, Claus H, Witte W. Decreased incidence of VanA-type Vancomycin-Resistant Enterococci isolated from poultry meat and from faecal samples of humans in the community after discontinuation of Avoparcin usage in animal husbandry. Microbial Drug Resistance. 1999;5(1):45–52. [PubMed: 10332721]
110.
Kola A, Kohler C, Pfeifer Y, Schwab F, Kühn K, Schulz K, et al. High prevalence of extended-spectrum-β-lactamase-producing Enterobacteriaceae in organic and conventional retail chicken meat, Germany. Journal of Antimicrobial Chemotherapy. 2012;67(11):2631–4. [PubMed: 22868643]
111.
Kruse H, Johansen BK, Rorvik LM, Schaller G. The Use of Avoparcin as a Growth Promoter and the Occurrence of Vancomycin-Resistant Enterococcus Species in Norwegian Poultry and Swine Production. Microbial Drug Resistance. 1999;5(2):135–9. [PubMed: 10432274]
112.
Kuhn I, Iversen A, Finn M, Greko C, Burman LG, Blanch AR, et al. Occurrence and relatedness of vancomycin-resistant enterococci in animals, humans, and the environment in different European regions. Appl Environ Microbiol. 2005;71(9):5383–90. [PMC free article: PMC1214655] [PubMed: 16151128]
113.
Lam TJGM, Engelen Ev, Scherpenzeel CGM, Hage JJ. Strategies to reduce antibiotic usage in dairy cattle in the Netherlands. Cattle Practice. 2012;20(3):163–71.
114.
Langlois BE, Cromwell GL, Stahly TS, Dawson KA, Hays VW. Antibiotic resistance of fecal coliforms after long-term withdrawal of therapeutic and subtherapeutic antibiotic use in a swine herd. Appl Environ Microbiol. 1983;46(6):1433–4. [PMC free article: PMC239589] [PubMed: 6660878]
115.
Langlois BE, Dawson K, Cromwell G, Stahly T. Antibiotic resistance in pigs following a 13 year ban. Journal of Animal Science. 1986;62(Suppl. 3):18–32.
116.
Larsen JL, Nielsen NC. Influence of restrictive use of antibiotics on the development of drug resistance in intestinal Escherichia coli from pigs (author’s transl). Nord Vet Med. 1975;27(7–8):353–64. [PubMed: 1099531]
117.
Lauderdale TL, Shiau YR, Wang HY, Lai JF, Huang IW, Chen PC, et al. Effect of banning vancomycin analogue avoparcin on vancomycin-resistant enterococci in chicken farms in Taiwan. Environ Microbiol. 2007;9(3):819–23. [PubMed: 17298380]
118.
Lebek G, Gubelmann P. Six years of official restriction on the use of antibiotics as feed additives in Switzerland. Random bacteriological sampling of faeces on farms./Sechs Jahre gesetzlich angeordnete Abstinenz von therapeutisch genutzten Antibiotika als nutritive Futterzusatze in der Schweiz-Tierfaeces-Stichproben in einigen landwirtschaftlichen Betrieben. Schweizer Archiv fur Tierheilkunde. 1979;121(6):295–309. [PubMed: 384512]
119.
Lee SK, Chon JW, Song KY, Hyeon JY, Moon JS, Seo KH. Prevalence, characterization, and antimicrobial susceptibility of Salmonella Gallinarum isolated from eggs produced in conventional or organic farms in South Korea. Poultry Science. 2013;92(10):2789–97. [PubMed: 24046429]
120.
LeJeune JT, Christie NP. Microbiological quality of ground beef from conventionally-reared cattle and “raised without antibiotics” label claims. Journal of Food Protection. 2004;67(7):1433–37. [PubMed: 15270497]
121.
Lenart-Boron A, Augustyniak K, Boron P. Screening of antimicrobial resistance and molecular detection of fluoroquinolone resistance mechanisms in chicken faeces-derived Escherichia coli. Veterinární Medicína. 2016;61(2):80–9.
122.
Lestari SI, Han F, Wang F, Ge B. Prevalence and antimicrobial resistance of Salmonella serovars in conventional and organic chickens from Louisiana retail stores. Journal of Food Protection. 2009;72(6):1165–72. [PubMed: 19610326]
123.
Looft T, Johnson TA, Allen HK, Bayles DO, Alt DP, Stedtfeld RD, et al. In-feed antibiotic effects on the swine intestinal microbiome. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(5):1691–6. [PMC free article: PMC3277147] [PubMed: 22307632]
124.
Lou R. Dietary mannan-oligosaccharide as an approach for altering prevalence of antibiotic resistance and distribution of tetracycline resistance determinants in fecal bacteria from swine [Ph.D.]. Ann Arbor: University of Kentucky; 1995.
125.
Luangtongkum T, Morishita TY, Ison AJ, Huang S, McDermott PF, Zhang Q. Effect of conventional and organic production practices on the prevalence and antimicrobial resistance of Campylobacter spp. in poultry. Appl Environ Microbiol. 2006;72(5):3600–7. [PMC free article: PMC1472326] [PubMed: 16672508]
126.
Mathew AG, Beckmann MA, Saxton AM. A comparsion of antibiotic resistance in bacteria isolated from swine herds in which antibiotics were used or excluded. Journal of Swine Health and Production. 2001;9(3):125–9.
127.
Mazengia E, Samadpour M, Hill HW, Greeson K, Tenney K, Liao G, et al. Prevalence, Concentrations, and Antibiotic Sensitivities of Salmonella Serovars in Poultry from Retail Establishments in Seattle, Washington. Journal of Food Protection. 2014;77(6):885–93. [PubMed: 24853509]
128.
Meemken D, Blaha T. Research on the occurrence of methicillin-resistant Staphylococcus aureus (MRSA) in domestic pigs and wild boars in Germany./Untersuchungen zum Vorkommen von Methicillin-resistenten Staphylococcus aureus (MRSA) bei Haus- und Wildschweinen. Deutsche Tierärztliche Wochenschrift. 2009;116(8):297–301.
129.
Mehboob A, Kocherginskaya SA, Aminov RI, Mackie RI. Quantitation of tetracycline resistance genes using Real-Time PCR on pig farms with and without antibiotic use. Abstracts of the General Meeting of the American Society for Microbiology. 2003;103:A-043.
130.
Millar JR. The relationship between use of apramycin in the poultry industry and the detection of gentamicin resistant E. coli in processed chickens. New Zealand Journal of Medical Laboratory Science. 2007;61(3):65–8.
131.
Millman J, Waits K, Grande H, Marks A, Marks J, Price L, et al. Prevalence of antibiotic-resistant E. coli in retail chicken: comparing conventional, organic, kosher, and raised without antibiotics [version 1; referees: 1 approved, 1 approved with reservations]. F1000Res. 2013;2(155):1–14. [PMC free article: PMC3901448] [PubMed: 24555073]
132.
Miranda CD, Rojas R. Occurrence of florfenicol resistance in bacteria associated with two Chilean salmon farms with different history of antibacterial usage. Aquaculture. 2007;266(1/4):39–46.
133.
Miranda JM, Guarddon M, Mondragon A, Vazquez BI, Fente CA, Cepeda A, et al. Antimicrobial resistance in Enterococcus spp. strains isolated from organic chicken, conventional chicken, and turkey meat: a comparative survey. Journal of Food Protection. 2007;70(4):1021–4. [PubMed: 17477278]
134.
Miranda JM, Guarddon M, Vázquez BI, Fente CA, Barros-Velázquez J, Cepeda A, et al. Antimicrobial resistance in Enterobacteriaceae strains isolated from organic chicken, conventional chicken and conventional turkey meat: a comparative survey. Food Control. 2008;19(4):412–6. [PubMed: 17477278]
135.
Miranda JM, Mondragon A, Vazquez BI, Fente CA, Cepeda A, Franco CM. Influence of farming methods on microbiological contamination and prevalence of resistance to antimicrobial drugs in isolates from beef. Meat Sci. 2009;82(2):284–8. [PubMed: 20416735]
136.
Miranda JM, Mondragón A, Vázquez BI, Fente CA, Cepeda A, Franco CM. Microbiological quality and antimicrobial resistance of Escherichia coli and Staphylococcus aureus isolated from conventional and organic “Arzúa-ulloa” cheese. CyTA - Journal of Food. 2009;7(2):103–10.
137.
Miranda JM, Vázquez BI, Fente CA, Barros-Velázquez J, Cepeda A, Abuín CMF. Antimicrobial resistance in Escherichia coli strains isolated from organic and conventional pork meat: a comparative survey. European Food Research and Technology. 2008;226(3):371–5.
138.
Miranda JM, Vazquez BI, Fente CA, Calo-Mata P, Cepeda A, Franco CM. Comparison of antimicrobial resistance in Escherichia coli, Staphylococcus aureus, and Listeria monocytogenes strains isolated from organic and conventional poultry meat. Journal of Food Protection. 2008;71(12):2537–42. [PubMed: 19244911]
139.
Mitchell R, Warnick LD, Ray K, Kaneene JB, Ruegg PL, Wells SJ, et al. Antimicrobial susceptibility of Salmonella isolates from organic and conventional dairy farms. In: Smith RA, editor. Proceedings of the Thirty-Seventh Annual Conference, American Association of Bovine Practitioners, Fort Worth, Texas, USA, 23–25 September, 2004. Stillwater; USA: American Association of Bovine Practitioners; 2004.
140.
Mollenkopf DF, Cenera JK, Bryant EM, King CA, Kashoma I, Kumar A, et al. Organic or antibiotic-free labeling does not impact the recovery of enteric pathogens and antimicrobial-resistant Escherichia coli from fresh retail chicken. Foodborne Pathog Dis. 2014;11(12):920–9. [PubMed: 25405393]
141.
Morley PS, Dargatz DA, Hyatt DR, Dewell GA, Patterson JG, Burgess BA, et al. Effects of Restricted Antimicrobial Exposure on Antimicrobial Resistance in Fecal Escherichia coli from Feedlot Cattle. Foodborne Pathog Dis. 2011;8(1):87–98. [PubMed: 21034271]
142.
Nannapaneni R, Hanning I, Wiggins KC, Story RP, Ricke SC, Johnson MG. Ciprofloxacin-resistant Campylobacter persists in raw retail chicken after the fluoroquinolone ban. Food Addit Contam. 2009;26(10):1348–53. [PubMed: 21462579]
143.
Noormohamed A, Fakhr MK. Prevalence and Antimicrobial Susceptibility of Campylobacter spp. in Oklahoma Conventional and Organic Retail Poultry. Open Microbiol J. 2014;8:130–7. [PMC free article: PMC4235082] [PubMed: 25408778]
144.
Norby B, Bartlett P, Kaneene J. Prevalence and Antimicrobial susceptibility of Campylobacter in antibiotic-free and conventional swine farms in the Mid-Western United States. IJMM International Journal of Medical Microbiology. 2003;293(Suppl. 35):53.
145.
Nugent C, Murdough P, Panky W, Barlow J. Establishing and comparing profiles of antimicrobial resistance in Staphylococcus aureus isolates from selected organic and conventional dairy farms in Vermont. Journal of Dairy Science. 2001;84(Suppl. 1):334.
146.
Nulsen MF, Mor MB, Lawton DE. Antibiotic resistance among indicator bacteria isolated from healthy pigs in New Zealand. N Z Vet J. 2008;56(1):29–35. [PubMed: 18322557]
147.
Nwankwo C, Ayogu T, Ifeanyichukwu I, Chika E, Nwakaeze E, Oji A, et al. Cloacal feacal carriage and occurrence of antibiotic resistant Escherichia coli in chicken grown with and without antibiotic supplemented feed. Journal of Veterinary Medicine and Animal Health. 2014;6(3):91–4.
148.
O’Brien AM, Hanson BM, Farina SA, Wu JY, Simmering JE, Wardyn SE, et al. MRSA in conventional and alternative retail pork products. PLoS ONE. 2012;7(1):e30092. [PMC free article: PMC3261874] [PubMed: 22276147]
149.
O’Neill C. Antibiotic-resistant staphylococci in the agricultural environment: reservoirs of resistance and infection [Ph.D.]. Ann Arbor: University of Warwick (United Kingdom); 2010.
150.
Obeng AS, Rickard H, Ndi O, Sexton M, Barton M. Antibiotic resistance, phylogenetic grouping and virulence potential of Escherichia coli isolated from the faeces of intensively farmed and free range poultry. Vet Microbiol. 2012;154:305–15. [PubMed: 21856098]
151.
Osadebe L-MU. Prevalence and Characteristics of Community associated Methicillin Resistant Staphylococcus areus (CA-MRSA) In Connecticut Swine Industry [Ph.D.]. Ann Arbor: Yale University; 2012.
152.
Pantosti A, Del Grosso M, Tagliabue S, Macri A, Caprioli A. Decrease of vancomycin-resistant enterococci in poultry meat after avoparcin ban. The Lancet. 1999;354(9180):741–42. [PubMed: 10475190]
153.
Park YK, Fox LK, Hancock DD, McMahan W, Park YH. Prevalence and antibiotic resistance of mastitis pathogens isolated from dairy herds transitioning to organic management. J vet sci. 2012;13(1):103–5. [PMC free article: PMC3317450] [PubMed: 22437543]
154.
Patchanee P. Epidemiology of Salmonella enterica related to swine production system and food safety [Ph.D.]. Ann Arbor: The Ohio State University; 2008.
155.
Peng M, Salaheen S, Almario JA, Tesfaye B, Buchanan R, Biswas D. Prevalence and antibiotic resistance pattern of Salmonella serovars in integrated crop-livestock farms and their products sold in local markets. Environ Microbiol. 2016;18(5):1654–65. [PubMed: 26914740]
156.
Pettey EA. Comparison of antibiotic susceptibility characteristics of fecal lactobacilli and the distribution of tetracycline resistance genes on two swine farms with different histories of antibiotic use [Ph.D.]. Ann Arbor: University of Kentucky; 2008.
157.
Pol M, Ruegg PL. Relationship between antimicrobial drug usage and antimicrobial susceptibility of gram-positive mastitis pathogens. Journal of Dairy Science. 2007;90(1):262–73. [PubMed: 17183094]
158.
Price LB, Johnson E, Vailes R, Silbergeld E. Fluoroquinolone-resistant Campylobacter isolates from conventional and antibiotic-free chicken products. Environ Health Perspect. 2005;113(5):557–60. [PMC free article: PMC1257547] [PubMed: 15866763]
159.
Price LB, Lackey LG, Vailes R, Silbergeld E. The persistence of fluoroquinolone-resistant Campylobacter in poultry production. Environ Health Perspect. 2007;115(7):1035–9. [PMC free article: PMC1913601] [PubMed: 17637919]
160.
Ray KA, Warnick LD, Mitchell RM, Kaneene JB, Ruegg PL, Wells SJ, et al. Antimicrobial susceptibility of Salmonella from organic and conventional dairy farms. Journal of Dairy Science. 2006;89(6):2038–50. [PubMed: 16702267]
161.
Reinstein S, Fox JT, Shi X, Alam MJ, Renter DG, Nagaraja TG. Prevalence of Escherichia coli O157:H7 in organically and naturally raised beef cattle. Applied and Environmental Microbiology. 2009;75(16):5421–3. [PMC free article: PMC2725470] [PubMed: 19542334]
162.
Rinsky JL, Nadimpalli M, Wing S, Hall D, Baron D, Price LB, et al. Livestock-associated methicillin and multidrug resistant Staphylococcus aureus is present among industrial, not antibiotic-free livestock operation workers in North Carolina. PLoS ONE 2013;8(7):e67641. [PMC free article: PMC3699663] [PubMed: 23844044]
163.
Roesch M, Perreten V, Doherr MG, Schaeren W, Schallibaum M, Blum JW. Comparison of antibiotic resistance of udder pathogens in dairy cows kept on organic and on conventional farms. Journal of Dairy Science. 2006;89(3):989–97. [PubMed: 16507693]
164.
Rollo SN, Norby B, Bartlett PC, Scott HM, Wilson DL, Fajt VR, et al. Prevalence and patterns of antimicrobial resistance in Campylobacter spp isolated from pigs reared under antimicrobial-free and conventional production methods in eight states in the Midwestern United States. J Am Vet Med Assoc. 2010;236(2):201–10. [PubMed: 20074013]
165.
Rossa LS, Stahlke EvR, Diez DC, Weber SH, Stertz SC, Macedo REFd. Antimicrobial resistance and occurrence of indicator and pathogenic bacteria in organic and conventional chicken meat: comparative study./Resistência antimicrobiana e ocorrência de micro-organismos patogênicos e indicadores em frangos orgânicos e convencionais: estudo comparativo. Biotemas. 2013;26(3):211–20.
166.
Salaheen S, Peng M, Biswas D. Ecological Dynamics of Campylobacter in Integrated Mixed Crop-Livestock Farms and Its Prevalence and Survival Ability in Post-Harvest Products. Zoonoses and Public Health. 2016;13:13. [PubMed: 27178350]
167.
Sanchez HM. Antibiotic Resistance in Bacteria Isolated from Commercial Meat Samples and Air Samples Near Agricultural Sites [Ph.D.]. Ann Arbor: University of California, Los Angeles; 2015.
168.
Sapkota AR, Hulet RM, Zhang G, McDermott P, Kinney EL, Schwab KJ, et al. Lower prevalence of antibiotic-resistant Enterococci on U.S. conventional poultry farms that transitioned to organic practices. Environ Health Perspect. 2011;119(11):1622–8. [PMC free article: PMC3226496] [PubMed: 21827979]
169.
Sapkota AR, Kim A, Hulet RM, McDermott P, Schwab KJ, Zhang G, et al. Trends in the Prevalence and Antibiotic-resistance of Salmonella After Conventional Poultry Farms Transition to Organic Practices. Abstracts of the General Meeting of the American Society for Microbiology. 2010;110:Q-1478.
170.
Sapkota AR, Kinney EL, George A, Hulet RM, Cruz-Cano R, Schwab KJ, et al. Lower prevalence of antibiotic-resistant Salmonella on large-scale U.S. conventional poultry farms that transitioned to organic practices. Sci Total Environ 2014;476–477:387–92. [PubMed: 24486494]
171.
Sato K, Bartlett PC, Kaneene JB, Downes FP. Comparison of prevalence and antimicrobial susceptibilities of Campylobacter spp. isolates from organic and conventional dairy herds in Wisconsin. Appl Environ Microbiol. 2004;70(3):1442–7. [PMC free article: PMC368295] [PubMed: 15006764]
172.
Sato K, Bartlett PC, Saeed MA. Antimicrobial susceptibility of Escherichia coli isolates from dairy farms using organic versus conventional production methods. J Am Vet Med Assoc. 2005;226(4):589–94. [PubMed: 15742702]
173.
Sato K, Bennedsgaard TW, Bartlett PC, Erskine RJ, Kaneene JB. Comparison of antimicrobial susceptibility of Staphylococcus aureus isolated from bulk tank milk in organic and conventional dairy herds in the midwestern United States and Denmark. Journal of Food Protection. 2004;67(6):1104–10. [PubMed: 15222534]
174.
Schmidt JW, Agga GE, Bosilevac JM, Wheeler TL, Arthur TM, editors. Variations in the fecal occurrences of antimicrobial-resistant bacteria are greater between seasons than between “raised without antibiotics” and “conventional” cattle production systems. 4th ASM conference on antimicrobial resistance in zoonotic bacteria and foodborne pathogens; 2015; Washington DC, USA.
175.
Schwaiger K, Schmied EM, Bauer J. Comparative analysis of antibiotic resistance characteristics of Gram-negative bacteria isolated from laying hens and eggs in conventional and organic keeping systems in Bavaria, Germany. Zoonoses and Public Health. 2008;55(7):331–41. [PubMed: 18667026]
176.
Schwaiger K, Schmied EM, Bauer J. Comparative analysis on antibiotic resistance characteristics of Listeria spp. and Enterococcus spp. isolated from laying hens and eggs in conventional and organic keeping systems in Bavaria, Germany. Zoonoses and Public Health. 2010;57(3):171–80. [PubMed: 19486494]
177.
Siemon CE, Bahnson PB, Gebreyes WA. Comparative investigations of prevalence and antimicrobial resistance of Salmonella between pasture and conventionally reared poultry. Avian Dis. 2007;51(1):112–17. [PubMed: 17461275]
178.
Sischo WM, Stevenson J, Kinder D. A case study of antibiotic use practices to change population level antibiotic resistance. Antimicrobial resistance in zoonotic bacteria and foodborne pathogens in animals, humans and the environment; Toronto, Canada;2010.
179.
Skjot-Rasmussen L, Ethelberg S, Emborg HD, Agerso Y, Larsen LS, Nordentoft S, et al. Trends in occurrence of antimicrobial resistance in Campylobacter jejuni isolates from broiler chickens, broiler chicken meat, and human domestically acquired cases and travel associated cases in Denmark. Int J Food Microbiol. 2009;131(2–3):277–9. [PubMed: 19345436]
180.
Smith HW, Lovell MA. Escherichia coli resistant to tetracyclines and to other antibiotics in the faeces of U.K. chickens and pigs in 1980. J Hyg (Lond). 1981;87(3):477–83. [PMC free article: PMC2134116] [PubMed: 7031130]
181.
Smith TC, Gebreyes WA, Abley MJ, Harper AL, Forshey BM, Male MJ, et al. Methicillin-resistant Staphylococcus aureus in pigs and farm workers on conventional and antibiotic-free swine farms in the USA. PLoS ONE. 2013;8(5):e63704. [PMC free article: PMC3646818] [PubMed: 23667659]
182.
Soonthornchaikul N. Resistance to antimicrobial agents in campylobacter isolated from chickens raised in intensive and organic farms and its implications for the management of risk to human health [Ph.D.]. Ann Arbor: Middlesex University (United Kingdom); 2006.
183.
Sørum M, Holstad G, Lillehaug A, Kruse H. Prevalence of Vancomycin Resistant Enterococci on Poultry Farms Established after the Ban of Avoparcin. Avian Dis. 2004;48(4):823–8. [PubMed: 15666863]
184.
Sørum M, Johnsen PJ, Aasnes B, Rosvoll T, Kruse H, Sundsfjord A, et al. Prevalence, Persistence, and Molecular Characterization of Glycopeptide-Resistant Enterococci in Norwegian Poultry and Poultry Farmers 3 to 8 Years after the Ban on Avoparcin. Appl Environ Microbiol. 2006;72(1):516–21. [PMC free article: PMC1352202] [PubMed: 16391086]
185.
Stegeman JA, Vernooij JCM, Khalifa OA, Van den Broek J, Mevius DJ. Establishing the change in antibiotic resistance of Enterococcus faecium strains isolated from Dutch broilers by logistic regression and survival analysis. Preventive Veterinary Medicine. 2006;74(1):56–66. [PubMed: 16488031]
186.
Struve T, Vigre H, Wingstrand A, Sørensen V, Jensen V, Lundsby K, et al. Effect of antimicrobial consumption on the occurence of resistence in conventional, free range and organic slaughter pig production in Denmark. 2nd ASM Conference on Antimicrobial Resistance in Zoonotic Bacteria and Foodborne Pathogens in Animals, Humans and the Environment; Toronto, Canada;2010.
187.
Suriyasathaporn W. Milk quality and antimicrobial resistance against mastitis pathogens after changing from a conventional to an experimentally organic dairy farm. Asian-Australasian Journal of Animal Sciences. 2010;23(5):659–64.
188.
Tadesse DA. Molecular epidemiology of Campylobacter and Yersinia enterocolitica isolates from pigs reared in conventional and antibiotic free farms from different geographic regions [Ph.D.]. Ann Arbor: The Ohio State University; 2009.
189.
Tamang MD, Gurung M, Nam HM, Moon DC, Kim SR, Jang GC, et al. Prevalence and characterization of Salmonella in pigs from conventional and organic farms and first report of S. serovar 1,4,[5],12:i:- from Korea. Vet Microbiol. 2015;178(1–2):119–24. [PubMed: 25982261]
190.
Teramoto H, Salaheen S, Debabrata B. Contamination of post-harvest poultry products with multidrug resistant Staphylococcus aureus in Maryland-Washington DC metro area. Food Control. 2016;65:132–35.
191.
Thakur S, Gebreyes WA. Prevalence and Antimicrobial Resistance of Campylobacter in Antimicrobial-Free and Conventional Pig Production Systems. Journal of Food Protection. 2005;68(11):2402–10. [PubMed: 16300080]
192.
Tikofsky LL, Barlow JW, Santisteban C, Schukken YH. A comparison of antimicrobial susceptibility patterns for Staphylococcus aureus in organic and conventional dairy herds. Microb Drug Resist. 2003;9(Suppl 1):S39–45. [PubMed: 14633366]
193.
Tragesser LA, Wittum TE, Funk JA, Winokur PL, Rajala-Schultz PJ. Association between ceftiofur use and isolation of Escherichia coli with reduced susceptibility to ceftriaxone from fecal samples of dairy cows. American Journal of Veterinary Research. 2006;67(10):1696–700. [PubMed: 17014318]
194.
Trost E, Mantel O, Dobrindt U. Genomic and phenotypic characterization of commensal E. coli isolates from chicken: Prevalence of virulence and resistance traits. International Journal of Medical Microbiology. 2013;303:63–4.
195.
Truszczyński M, Pejsak Z. Influence of antibiotics used in animals on antibiotic resistance to bacteria pathogenic for man./Wpyw stosowania u zwierzat antybiotyków na lekooporność bakterii chorobotwórczych dla czowieka. Medycyna Weterynaryjna. 2006;62(12):1339–43.
196.
van den Bogaard AE, Bruinsma N, Stobberingh EE. The effect of banning avoparcin on VRE carriage in The Netherlands. Journal of Antimicrobial Chemotherapy. 2000;46(1):146–8. [PubMed: 10882707]
197.
van den Bogaard AE, London N, Driessen C, Stobberingh EE. Antibiotic resistance of faecal Escherichia coli in poultry, poultry farmers and poultry slaughterers. Journal of Antimicrobial Chemotherapy. 2001;47(6):763–71. [PubMed: 11389108]
198.
Veldman K, Dierikx C, Testerink J, Japing M, Kant A, van Essen-Zandbergen A, et al., editors. Decrease of antimicrobial resistance in E. coli from animal husbandry reflects the reduction of antibiotic usage in animals in the Netherlands. 24th European Congress of Clinical Microbiology and Infectious Diseases; 2014; Barcelona, Spain.
199.
Walk ST, Mladonicky JM, Middleton JA, Heidt AJ, Cunningham JR, Bartlett P, et al. Influence of antibiotic selection on genetic composition of Escherichia coli populations from conventional and organic dairy farms. Appl Environ Microbiol. 2007;73(19):5982–9. [PMC free article: PMC2074991] [PubMed: 17704272]
200.
Warnick L, Ray K, Mitchell R, Kaneene J, Ruegg P, Wells H, et al. Salmonella antimicrobial resistance on organic and conventional dairy farms. Science - Prevention - Control;2015.
201.
Wyckoff TJ, Wyckoff PH, Hanson JA, Davison JM, Gerber MM, Skala JR. Changes in Antimicrobial Susceptibility of Staphylococcus Milk Isolates from a West-Central Minnesota Dairy Herd During Transition to Organic Management. Abstracts of the General Meeting of the American Society for Microbiology. 2012;112:3156.
202.
Zawack K, Li M, Booth JG, Love W, Lanzas C, Grohn YT. Monitoring Antimicrobial Resistance in the Food Supply Chain and its Implications for FDA Policy Initiatives. Antimicrob Agents Chemother. 2016;20:20. [PMC free article: PMC4997833] [PubMed: 27324772]
203.
Zhang J, Massow A, Stanley M, Papariella M, Chen X, Kraft B, et al. Contamination rates and antimicrobial resistance in Enterococcus spp., Escherichia coli, and Salmonella isolated from “no antibiotics added”-labeled chicken products. Foodborne Pathog Dis. 2011;8(11):1147–52. [PubMed: 21714636]
204.
Zhang J, Wall SK, Xu L, Ebner PD. Contamination rates and antimicrobial resistance in bacteria isolated from “grass-fed” labeled beef products. Foodborne Pathog Dis. 2010;7(11):1331–6. [PubMed: 20618073]
205.
Zhang Y. Antimicrobial resistance of Listeria monocytogenes and Enterococcus faecium from food and animal sources [Ph.D.]. Ann Arbor: University of Maryland, College Park; 2005.
206.
Zwonitzer MR, Soupir ML, Jarboe LR, Smith DR. Quantifying Attachment and Antibiotic Resistance of from Conventional and Organic Swine Manure. J Environ Qual. 2016;45(2):609–17. [PubMed: 27065408]
207.
Dorado-Garcia A, Mevius DJ, Jacobs JJH, Van Geijlswijk IM, Mouton JW, Wagenaar JA, et al. Quantitative assessment of antimicrobial resistance in livestock during the course of a nationwide antimicrobial use reduction in the Netherlands. Journal of Antimicrobial Chemotherapy. 2016;71(12):3607–19. [PubMed: 27585970]
208.
Kassem II, Kehinde O, Kumar A, Rajashekara G. Antimicrobial-Resistant Campylobacter in Organically and Conventionally Raised Layer Chickens. Foodborne Pathog Dis. 2017;14(1):29–34. [PubMed: 27768387]
209.
Osterberg J, Wingstrand A, Jensen AN, Kerouanton A, Cibin V, Barco L, et al. Antibiotic resistance in Escherichia coli from pigs in organic and conventional farming in four European countries. PLoS ONE 2016;11 (6) (e0157049). [PMC free article: PMC4928804] [PubMed: 27362262]
210.
Wanninger S, Donati M, Di Francesco A, Hassig M, Hoffmann K, Seth-Smith HMB, et al. Selective pressure promotes tetracycline resistance of Chlamydia suis in fattening pigs. PLoS ONE 2016;11 (11)(e0166917). [PMC free article: PMC5125646] [PubMed: 27893834]
211.
Casewell M, Friis C, Marco E, McMullin P, Phillips I. The European ban on growth-promoting antibiotics and emerging consequences for human and animal health. Journal of Antimicrobial Chemotherapy. 2003;52(2):159–61. [PubMed: 12837737]
212.
Smith-Spangler C, Brandeau ML, Hunter GE, Bavinger JC, Pearson M, Eschbach PJ, et al. Are organic foods safer or healthier than conventional alternatives?: a systematic review. Ann Intern Med. 2012;157(5):348–66. [PubMed: 22944875]
213.
Wilhelm B, Rajic A, Waddell L, Parker S, Harris J, Roberts KC, et al. Prevalence of zoonotic or potentially zoonotic bacteria, antimicrobial resistance, and somatic cell counts in organic dairy production: current knowledge and research gaps. Foodborne Pathog Dis. 2009;6(5):525–39. [PubMed: 19422303]
214.
Young I, Rajic A, Wilhelm BJ, Waddell L, Parker S, McEwen SA. Comparison of the prevalence of bacterial enteropathogens, potentially zoonotic bacteria and bacterial resistance to antimicrobials in organic and conventional poultry, swine and beef production: a systematic review and meta-analysis. Epidemiol Infect. 2009;137(9):1217–32. [PubMed: 19379542]
215.
Lazarus B, Paterson DL, Mollinger JL, Rogers BA. Do human extraintestinal Escherichia coli infections resistant to expanded-spectrum cephalosporins originate from food-producing animals? A systematic review. Clin Infect Dis. 2015;60(3):439–52. [PubMed: 25301206]
216.
Aarestrup FM. The livestock reservoir for antimicrobial resistance: a personal view on changing patterns of risks, effects of interventions and the way forward. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2015;370(1670):20140085. [PMC free article: PMC4424434] [PubMed: 25918442]
217.
Centers for Disease Control and Prevention. One Health 2013 [Available from: http://www​.cdc.gov/onehealth/.
218.
. Uses of Antimicrobials in Food Animals in Canada: Impact on Resistance and Human Health. Report of the Advisory Committee on Animal Uses of Antimicrobials and Impact on Resistance and Human Health. 2002.
219.
Council of the European Union. Council conclusions on the impact of antimicrobial resistance in the human health sector and in the veterinary sector – a “One Health” perspective. In: 3177th Employment SP, Health and Cosumer Affairs Council meeting, editor. Luxembourg;2012. p. 6.
220.
Queenan K, Hasler B, Rushton J A. One Health approach to antimicrobial resistance surveillance: is there a business case for it? Int J Antimicrob Agents 2016. [PubMed: 27496533]
221.
Khan LH. One Health and the Politics of Antimicrobial Resistance. Baltimore: Johns Hopkins University Press; 2016.
222.
Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A. 2015;112(18):5649–54. [PMC free article: PMC4426470] [PubMed: 25792457]

APPENDIX 1. MEDLINE search strategy

#SearchesResults
1exp Poultry/135574
2exp Ruminants/447143
3exp Swine/193661
4exp Bees/9624
5exp Fishes/154782
6exp Seafood/11624
7exp Mollusca/52115
8exp Crustacea/35148
9(food animal* or farm* or production animal* or livestock or feedlot* or animal feeding operation* or AFO or CAFO).kw,tw.78843
10(ruminant* or cattle or bovine or cow* or beef or heifer* or steer* or calf or calves or sheep or ovine or caprine or goat* or equine or horse* or lepine or rabbit* or deer or elk or game or buffalo or bison or swine or pork or pig* or hog* or boar*).kw,tw.1164249
11(chicken* or broiler* or turkey* or duck* or geese or goose or poultry or fowl or avian).kw,tw.175957
12(bee or bees or honeybee* or apiary or apicultur*).kw,tw.14422
13((farm* or aquaculture) adj2 (fish or shellfish or seafood or amberjack or arapaima or asp or atipa or barb or barramundi or bass or beluga or bluefin or bluefish or bocachico or bonythongue or bream or bullhead or carp or catfish or char or cichlid or cobia or cod or dorada or eel* or gourami or guapote or grouper or halibut or lai or loach or mackerel or mandarin fish or meagre fish or milkfish or mojarra or mullet or mudfish or nori nei or perch or pejerrey or pike or porgy or pompano or red drum or roach or roho labeo or salmon or sampa or seabass or seabream or snakehead or snapper or snook or sole or spinefood or sturgeon or sweetfish or tench or tilapia or trout or tuna or turbot or vendace or whitefish)).kw,tw.3753
14((farm* or aquaculture) adj2 (shrimp or prawn* or crayfish or lobster* or crab*)).kw,tw.615
15((farm* or aquaculture) adj2 (abalone or bivalve* or clam* or carpet shell or cockle* or corbicula or geoduck or mussel* or oyster* or periwinkle* or quahog or sand gaper* or scallop* or shellfish or tagelus or venus)).kw,tw.439
16aquaculture.kw,tw.6172
17Aquaculture/4788
181 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 171832370
19drug resistance, microbial/or exp drug resistance, bacterial/122825
20((antibacterial or anti-bacterial or antibiotic or anti-biotic or antimicrobial or anti-microbial) adj2 (resistan* or susceptib* or minimum inhibitory concentration)).kw,tw.52123
21((aldesulfone or amdinopenicillin* or amikacin or aminocyclitol* or aminoglycoside* or aminopenicillin* or amoxicillin* or ampicillin or amphenicol* or ansamycin* or antipseudomonal or antistaphylococcal or apramycin or arbekacin or aspoxicillin or avilamycin or avoparcin or azalide or azidocillin or azithromycin or azlocillin or aztreonam or bacampicillin or bacitracin or baquiloprim or bekanamycin or benzylpenicillin or biapenem or bicozamycin or bicyclomycin* or brodimoprim or calcium aminosalicylate or capreomycin or carbadox or carbapenem* or carbenicillin or carboxypenicillin* or carindacillin or carumonam or cef* or cepha* or chloramphenicol or chlortetracycline or cinoxacin or ciprofloxacin or clarithromycin or clindamycin or clofazimine or clometocillin or clomocycline or cloxacillin or colistin or cyclic ester* or cyclic polypeptide* or cycloserine or dalbavancin or dalfopristin or danofloxacin or dapsone or daptomycin or demeclocycline or diaminopyrimidine* or dibekacin or dicloxacillin or difloxacin or dirithromycin or dihydrostreptomycin or doripenem or doxycycline or dihydrofolate reductase inhibitor* or enoxacin or enramycin or enrofloxacin or epicillin or ertapenem or erythromycin or ethambutol or ethionamide or faropenem or fleroxacin or flomoxef or florphenicol or flucloxacillin or flumeqin* or fluoroquinolone* or flurithromycin or fosfomycin or framycetin or furaltadone or furazolidone or fusidic acid or gamithromycin or garenoxacin or gatifloxacin or gemifloxacin or gentamicin or glycopeptide* or glycylcycline* or gramicidin or grepafloxacin or hetacillin or ibafloxacin or iclaprim or imipenem or ionophore* or isepamicin or isoniazid or josamycin or kanamycin or ketolilde* or kitasamycin or lasalocid or latamoxef or levofloxacin or lincomycin or lincosamide* or linezolid or lipopeptide* or lomefloxacin or loracarbef or lymecycline or macrolide* or maduramycin or marbofloxacin or mecillinam or meropenem or metacycline or metampicillin or methicillin or meticillin or metronidazole or mezlocillin or midecamycin or miloxacin or miocamycin or minocycline or mirosamycin or monensin or monobactam* or morinamide or moxifloxacin or mupirocin or nafcillin or nalidixic acid or narasin or neomycin or netilmicin or nifurtoinol or nitrofur* or nitroimidazole* or norfloxacin or novobiocin or ofloxacin or oleandomycin or orbifloxacin or oritavancin or ormosulfathiazole or ornidazole or orthosomycin* or oxacillin or oxazolidinone* or oxolinic acid or oxytetracycline or panipenem or para-aminosalicylic acid or paromomycin or pazufloxacin or pefloxacin or penamecillin or penethatamate or penicillin* or penimepicycline or phenethicillin or pheneticillin or phenicol* or phenoxypenicillin* or phenoxymethylpenicillin or phthalylsulfathiazole or pipemidic acid or piperacillin or pirlimycin or piromidic acid or pivampicillin or pivmecillinam or pleuromutilin* or polymixin* or polymyxin* or polypeptide* or pristinamycin or propicillin or protionamide or prulifloxacin or pseudomonic acid* or pyrazinamide or pyrimethamine or quinolone* or quinoxaline* or quinupristin or retapamulin or ribostamycin or rifa* or riminofenazine* or rokitamycin or rolitetracycline or rosoxacin or roxithromycin or rufloxacin or salfadoxine or salinomycin or semduramicin or sisomicin or sitafloxacin or sodium aminosalicylate or sparfloxacin or spectinomycin or spiramycin or streptoduocin or streptogramin* or streptomycin or sulbenicillin or sulfachlorpyridazine or sulfadi* or sulfafurazole or sulfaisodimidine or sulfisoxazole or sulfon* or sulfaguanidine or sulfam* or sulfon* or sulfanilamide or sulfafurazole or sulfalene or sulfam* or sulfanilamide or sulfap* or sulfaquinoxaline or sulfath* or sultamicillin or talampicillin or teicoplanin or telavancin or telithromycin or temafloxacin or temocillin or terdecamysin or terizidone or tetracycline* or tetroxoprim or thiamphenicol or tiamulin or ticarcillin or tigecycline or tildipirosin or tilmicosin or tinidazole or tiocarlide or tobicillin or tobramycin or trimethoprim or troleandomycin or trovafloxacin or tulathromycin or tylosin or tylvalosin or valnemulin or vancomycin or virginiamycin) adj2 (resistan* or susceptib* or minimum inhibitory concentration)).kw,tw.93911
22exp Drug Resistance/273591
23exp Anti-Bacterial Agents/or exp Animal Feed/654369
24(antibacterial or anti-bacterial or antibiotic or anti-biotic or antimicrobial or anti- microbial).kw,tw.291134
2523 or 24791722
2622 and 25102558
27AMR.kw,tw.1504
2819 or 20 or 21 or 26 or 27 ((reduc* or decreas* or restrict* or limit* or ban or bans or banning or eliminat* or control* or188126
29regulat* or less* or cut* or scale* or scaling or down* or taper*) adj5 (“use” or usage or utilization or dose* or dosage or administ* or prescri*)).kw,tw.427628
30(organic or (antibiotic adj2 free) or without antibiotic* or without antimicrobial*).kw,tw.216036
3129 or 30640063
3218 and 28 and 31849
33remove duplicates from 32835

Notes on search terms:

APPENDIX 2. Grey literature search strategy

The following websites/agencies/documents were included in our grey literature search:

1. CANADA

1.1. Canadian Antimicrobial Resistance Alliance (http://www.can-r.com)

Manuscripts

1.2. Public Health Agency

Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) (http://www.phac-aspc.gc.ca/cipars-picra/index-eng.php)

Canadian Antimicrobial Resistance Surveillance System Reports 2013 – 2015

Canadian Nosocomial Infection Surveillance Program (CNISP) (http://www.phac-aspc.gc.ca/nois-sinp/survprog-eng.php)

-

Surveillance projects

-

Publications

1.3. Health Canada

Antimicrobial resistance section (http://www.hc-sc.gc.ca/dhp-mps/vet/antimicrob/index-eng.php)

1.4. Canadian Institutes of Health Research (http://www.cihr-irsc.gc.ca)

Health Services and Policy Research

-

Publications

Population and Public Health

-

Publications

2. DENMARK

DANMAP (http://www.danmap.org/)

-

Reports

7. EUROPEAN UNION

7.2. European Centre for Disease Prevention and Control (ECDC)

European Antimicrobial Resistance Surveillance Network (EARS-Net) (http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx)

European Surveillance of Antimicrobial Consumption (ESAC-Net) (http://ecdc.europa.eu/en/activities/surveillance/ESAC-Net/Pages/index.aspx)

7.3. European Food Safety Authority (EFSA)

Antimicrobial resistance (http://www.efsa.europa.eu/en/topics/topic/amr)

-

Completed work

7.4. European Medicines Agency (EMA)

European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000302.jsp)

Antimicrobial Resistance (http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001686.jsp&mid=WC0b01ac05807a4e0d)

-

ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals

8. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)

Antibiotic/Antimicrobial Resistance (https://www.cdc.gov/drugresistance/)

-

Digital Materials (https://www​.cdc.gov/drugresistance​/resources​/digital_materials.html)

-

Publications (https://www​.cdc.gov/drugresistance​/resources/publications​.html)

-

National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS) (http://www​.cdc.gov/narms/index.html)

  • Publications section
-

Translatlantic Task Force on Antimicrobial Resistance (TATFAR) (https://www​.cdc.gov/drugresistance​/tatfar/index.html)

  • Links and Resources
-

Interagency Taskforce on Antimicrobial Resistance (ITFAR) (http://www​.cdc.gov/drugresistance​/itfar/index.html

  • ITFAR Link and Resources

9. US FOOD AND DRUG ADMINISTRATION (FDA)

Antimicrobial Resistance (http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/)

-

Guidance for Industry #209

10. JOINT PROGRAMMING INITIATIVE ON ANTIMICROBIAL RESISTANCE (http://www.jpiamr.eu/)

Library

Workshop reports

Papers

12. WORLD HEALTH ORGANIZATION (WHO)

12.1. IRIS Repository (http://apps.who.int/iris/)

Search “antimicrobial resistance”

Antimicrobial use in aquaculture and antimicrobial resistance

-

Antimicrobial resistance and rational use of antimicrobial agents (EM/RC49/8)

-

Use of antimicrobials in food animals (weekly epidemiological record, no. 33, 18 August 2000)

-

Impacts of antimicrobial growth promoter termination in Denmark

-

Joint FAO/OIE/WHO Expert Workshop on Non-Human Antimicrobial Usage and Antimicrobial Resistance: Scientific assessment

-

Second Joint FAO/OIE/WHO Expert Workshop on Non-Human Antimicrobial Usage and Antimicrobial Resistance: Management options

-

The Medical Impact of Antimicrobial Use in Food Animals. Report of a WHO Meeting. Berlin, Germany, 13–17 October 1997

-

Containing Antimicrobial Resistance (WHO/CDS/CSR/DRS/99/2)

-

WHO Scientific working group on monitoring and management on bacterial resistance to antimicrobial agents (WHO/CDS/BVI/95.7)

-

Regional strategy on prevention and containment of antimicrobial resistance 2010–2015

-

Use of quinolones in food animals and potential impact on human health (WHO/EMC/ZDI/98.12)

12.2. Strategic and Technical Advisory Group (STAG) on antimicrobial resistance (http://www.who.int/antimicrobial-resistance/events/stag/en/)

6th meeting 11 May 2016

5th meeting 23–24 November 2015

4th meeting 24–25 February 2015

3rd meeting 17 October 2014

2nd meeting 14–16 April 2014

1st meeting 19–20 September 2013

12.3. International Clinical Trials Registry Platform (http://apps.who.int/trialsearch/Default.aspx) List by “Health Topics”

-

Antimicrobial Resistance

-

Epidemiology

13. INTERNATIONAL VETERINARY INFORMATION SERVICE (http://www.ivis.org/home.asp)

Search “antimicrobial resistance”

14. EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECITOUS DISEASES (ESCMID)

14.1. eLibrary (https://www.escmid.org/escmid_publications/escmid_elibrary/)

Search “antimicrobial use animals”

-

Checked all items until achieve 50% of relevance scale

14.3. The Lancet/ESCMID Conference on healthcare-associated infections and antimicrobial resistance (https://www.escmid.org/research_projects/escmid_conferences/past_escmid_conferences/hai_and_ab_resistance/)

15. ReACT (http://www.reactgroup.org/)

Policy and Reports

16. CONSUMERS INTERNATIONAL

WCRD 2016: Antibiotic Resistance (http://www.consumersinternational.org/our-work/wcrd/wcrd-2016/)

-

WCRD 2016 Resource Pack

17. WORLD ORGANIZATION FOR ANIMAL HEALTH (OIE)

Antimicrobial Resistance (http://www.oie.int/en/for-the-media/amr/)

OIE Global Conference on the Prudent Use of Antimicrobial Agents for Animals

-

Presentations/Abstracts (http://www​.oie.int/eng​/A_AMR2013/presentations.htm)

19. FOOD AND AGRICULTURAL ORGANIZATION OF THE UNITED NATIONS (FAO)

Antimicrobial Resistance (http://www.fao.org/antimicrobial-resistance/en/)

-

Publications section

-

Uso de antimicrobianos en animales de consumo (http://www​.fao.org/3/a-y5468s.pdf)

-

Joint FAO/WHO/OIE Expert Meeting on Critically Important Antimicrobials (ftp://ftp​.fao.org/docrep​/fao/010/i0204e/i0204e00.pdf)

-

CODEX Alimentarius

21. AMERICAN VETERINARY MEDICAL ASSOCIATION (AVMA)

Antimicrobial Resistance FAQs (https://www.avma.org/KB/Resources/FAQs/Pages/Antimicrobial-Use-and-Antimicrobial-Resistance-FAQs.aspx)

22. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)

NIAID’s Antibacterial Resistance Program: Current Status and Future Directions (http://www.niaid.nih.gov/topics/antimicrobialResistance/Documents/ARstrategicplan2014.pdf)

23. CLINICALTRIALS.GOV

Search “Antimicrobial Animal”

24. INNOVATIVE MEDICINES INITIATIVE (IMI)

Combating antimicrobial resistance in Europe (COMBACTE) (http://www.imi.europa.eu/content/combacte)

-

Projects

25. LIST OF CONFERENCE PROCEEDINGS FROM SCIENTIFIC MEETINGS

Proceedings/presentations from the following conferences/meetings were manually reviewed and abstracts were selected based on the eligibility criteria described in the methods section of the report:

  • ASM Conference on Antimicrobial Resistance in Zoonotic Bacteria and Foodborne Pathogens
    Denmark, 2008
  • 2nd ASM Conference on Antimicrobial Resistance in Zoonotic Bacteria and Foodborne Pathogens in Animals, Humans and the Environment
    Canada, 2010
  • 3rd ASM Conference on Antimicrobial Resistance in Zoonotic Bacteria and Foodborne Pathogens in Animals, Humans and the Environment
    France, 2012
  • 4th ASM Conference on Antimicrobial Resistance in Zoonotic Bacteria and Foodborne Pathogens
    United States, 2015
  • 2009 - ASM-ESCMID Conference on Methicillin-resistant Staphylococci in Animals
    England, 2009
  • 2011 - Methicillin-resistant Staphylococci in Animals: Veterinary and Public Health Implications
    United States, 2011
  • 3rd ASM-ESCMID Methicillin-resistant Staphylococci in Animals: Veterinary and Public Health Implications
    Denmark, 2013
  • 4th ASM-ESCMID Conference on Methicillin-resistant Staphylococci in Animals: Veterinary and Public Health Implications
    United States 2015
  • American Society for Microbiology 110th – 115th General Meetings
  • ASM-ESCMID International Workshop on Dermatological Infections and Food-borne Diseases
    United States, 2015
  • 2010 International Conference on Antimicrobial Research
    Spain, 2010
  • 2012 International Conference on Antimicrobial Research
    Portugal, 2012
  • 2014 International Conference on Antimicrobial Research
    Spain, 2014
  • 2016 International Conference on Antimicrobial Research
    Spain, 2016
  • National Foundation for Infectious Diseases 2002 Conference on Antimicrobial Resistance
    United States, 2002
  • National Foundation for Infectious Diseases 2003 Conference on Antimicrobial Resistance
    United States, 2003
  • National Foundation for Infectious Diseases 2004 Conference on Antimicrobial Resistance
    United States, 2004
  • National Foundation for Infectious Diseases 2005 Conference on Antimicrobial Resistance
    United States, 2005
  • National Foundation for Infectious Diseases 2006 Conference on Antimicrobial Resistance
    United States, 2006
  • National Foundation for Infectious Diseases 2007 Conference on Antimicrobial Resistance
    United States, 2007
  • National Foundation for Infectious Diseases 2008 Conference on Antimicrobial Resistance
    United States, 2008
  • National Foundation for Infectious Diseases 2010 Conference on Antimicrobial Resistance
    United States, 2010
  • 2015 Meeting of the Transatlantic Taskforce on Antimicrobial Resistance
    Luxembourg, 2015
  • CDC 64th Epidemic Intelligence Service
    United States, 2015
  • 14th International Congress on Infectious Diseases
    United States, 2010
  • 15th International Congress on Infectious Diseases
    Thailand, 2012
  • 16th International Congress on Infectious Diseases
    South Africa, 2014
  • 17th International Congress on Infectious Diseases
    India, 2016
  • 2007 International Meeting on Emerging Diseases and Surveillance
    Austria, 2007
  • 2009 International Meeting on Emerging Diseases and Surveillance
    Austria, 2009
  • 2011 International Meeting on Emerging Diseases and Surveillance
    Austria, 2011
  • 2013 International Meeting on Emerging Diseases and Surveillance
    Austria, 2013
  • 2014 International Meeting on Emerging Diseases and Surveillance
    Austria, 2014
  • 22nd World Buiatrics Congress
    Germany, 2002
  • 23rd World Buiatrics Congress
    Canada, 2004
  • 24th World Buiatrics Congress
    France, 2006
  • 25th World Buiatrics Congress
    Hungary, 2008
  • 26th World Buiatrics Congress
    Chile, 2010
  • 27th World Buiatrics Congress
    Portugal, 2012
  • 28th World Buiatrics Congress
    Australia, 2014
  • 2010 National Mastitis Council Annual Meeting
    United States, 2010
  • 2011 National Mastitis Council Annual Meeting
    United States, 2011
  • 2012 National Mastitis Council Annual Meeting
    United States, 2012
  • 2013 National Mastitis Council Annual Meeting
    United States, 2013
  • 2014 National Mastitis Council Annual Meeting
    United States, 2014
  • 2015 National Mastitis Council Annual Meeting
    United States, 2015
  • 2011 International Meeting on Neglected Tropical Diseases
    United States, 2011

APPENDIX 3. Study characteristics flow charts

Figure 1. Flowchart depicting the species, sample point, sample type and bacteria investigated within studies where organic production systems, which reduced or eliminated antibiotic use in animals, were implemented.

Figure 1Flowchart depicting the species, sample point, sample type and bacteria investigated within studies where organic production systems, which reduced or eliminated antibiotic use in animals, were implemented

*

Faeces includes caecum samples, cloacal swabs, rectal swabs, intestinal tract, colon content

Figure 2. Flowchart depicting species, sample point, sample type and bacteria investigated within studies where externally imposed bans or restrictions were placed on antibiotic use in food animals.

Figure 2Flowchart depicting species, sample point, sample type and bacteria investigated within studies where externally imposed bans or restrictions were placed on antibiotic use in food animals

*

Faeces includes caecum samples and cloacal swabs

Figure 3. Flowchart depicting the species, sample point, sample type and bacteria investigated within studies with interventions that were self-identified to be antibiotic free, raised without antibiotics, or other similar labels.

Figure 3Flowchart depicting the species, sample point, sample type and bacteria investigated within studies with interventions that were self-identified to be antibiotic free, raised without antibiotics, or other similar labels

*

Faeces includes rectal swabs and caecum content

Figure 4. Flowchart depicting the species, sample point, sample type and bacteria investigated in studies where there was a voluntary limitation on the use of antibiotics within production systems.

Figure 4Flowchart depicting the species, sample point, sample type and bacteria investigated in studies where there was a voluntary limitation on the use of antibiotics within production systems

*

Faeces includes cloacal swabs, rectal swabs, and caecum samples

APPENDIX 4. Forest plots

Figure 2. Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Enterobacteriaceae isolates in faecal samples.

Figure 2

Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Enterobacteriaceae isolates in faecal samples.

Figure 3. Forest plot of absolute risk differences of antibiotic resistance to cephalosporins for Enterobacteriaceae isolates in faecal samples.

Figure 3

Forest plot of absolute risk differences of antibiotic resistance to cephalosporins for Enterobacteriaceae isolates in faecal samples.

Figure 4. Forest plot of absolute risk differences of antibiotic resistance to penicillins for Enterobacteriaceae isolates in faecal samples.

Figure 4

Forest plot of absolute risk differences of antibiotic resistance to penicillins for Enterobacteriaceae isolates in faecal samples.

Figure 5. Forest plot of absolute risk differences of antibiotic resistance to quinolones for Enterobacteriaceae isolates in faecal samples.

Figure 5

Forest plot of absolute risk differences of antibiotic resistance to quinolones for Enterobacteriaceae isolates in faecal samples.

Figure 6. Forest plot of absolute risk differences of antibiotic resistance to sulfonamides for Enterobacteriaceae isolates in faecal samples.

Figure 6

Forest plot of absolute risk differences of antibiotic resistance to sulfonamides for Enterobacteriaceae isolates in faecal samples.

Figure 9. Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Enterobacteriaceae isolates in meat samples.

Figure 9

Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Enterobacteriaceae isolates in meat samples.

Figure 10. Forest plot of absolute risk differences of antibiotic resistance to cephalosporins for Enterobacteriaceae isolates in meat samples.

Figure 10

Forest plot of absolute risk differences of antibiotic resistance to cephalosporins for Enterobacteriaceae isolates in meat samples.

Figure 11. Forest plot of absolute risk differences of antibiotic resistance to penicillins for Enterobacteriaceae isolates in meat samples.

Figure 11

Forest plot of absolute risk differences of antibiotic resistance to penicillins for Enterobacteriaceae isolates in meat samples.

Figure 12. Forest plot of absolute risk differences of antibiotic resistance to quinolones for Enterobacteriaceae isolates in meat samples.

Figure 12

Forest plot of absolute risk differences of antibiotic resistance to quinolones for Enterobacteriaceae isolates in meat samples.

Figure 13. Forest plot of absolute risk differences of antibiotic resistance to sulfonamides for Enterobacteriaceae isolates in meat samples.

Figure 13

Forest plot of absolute risk differences of antibiotic resistance to sulfonamides for Enterobacteriaceae isolates in meat samples.

Figure 16. Forest plot of absolute risk differences in antibiotic resistance to glycopeptides for Enterococcus spp. isolates in faecal samples.

Figure 16

Forest plot of absolute risk differences in antibiotic resistance to glycopeptides for Enterococcus spp. isolates in faecal samples.

Figure 17. Forest plot of absolute risk differences in antibiotic resistance to macrolides for Enterococcus spp. isolates in faecal samples.

Figure 17

Forest plot of absolute risk differences in antibiotic resistance to macrolides for Enterococcus spp. isolates in faecal samples.

Figure 18. Forest plot of absolute risk differences in antibiotic resistance to penicillins for Enterococcus spp. isolates in faecal samples.

Figure 18

Forest plot of absolute risk differences in antibiotic resistance to penicillins for Enterococcus spp. isolates in faecal samples.

Figure 19. Forest plot of absolute risk differences in antibiotic resistance to streptogramins for Enterococcus spp. isolates in faecal samples.

Figure 19

Forest plot of absolute risk differences in antibiotic resistance to streptogramins for Enterococcus spp. isolates in faecal samples.

Figure 22. Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Campylobacter spp. isolates in faecal samples.

Figure 22

Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Campylobacter spp. isolates in faecal samples.

Figure 23. Forest plot of absolute risk differences of antibiotic resistance to macrolides for Campylobacter spp. isolates in faecal samples.

Figure 23

Forest plot of absolute risk differences of antibiotic resistance to macrolides for Campylobacter spp. isolates in faecal samples.

Figure 24. Forest plot of absolute risk differences of antibiotic resistance to penicillins for Campylobacter spp. isolates in faecal samples.

Figure 24

Forest plot of absolute risk differences of antibiotic resistance to penicillins for Campylobacter spp. isolates in faecal samples.

Figure 25. Forest plot of absolute risk differences of antibiotic resistance to quinolones for Campylobacter spp. isolates in faecal samples.

Figure 25

Forest plot of absolute risk differences of antibiotic resistance to quinolones for Campylobacter spp. isolates in faecal samples.

Figure 31. Forest plot of absolute risk differences in antibiotic resistance to lincosamides for Staphylococcus spp. isolates in milk samples.

Figure 31

Forest plot of absolute risk differences in antibiotic resistance to lincosamides for Staphylococcus spp. isolates in milk samples.

Figure 32. Forest plot of absolute risk differences in antibiotic resistance to macrolides for Staphylococcus spp. isolates in milk samples.

Figure 32

Forest plot of absolute risk differences in antibiotic resistance to macrolides for Staphylococcus spp. isolates in milk samples.

Figure 33. Forest plot of absolute risk differences in antibiotic resistance to penicillins for Staphylococcus spp. isolates in milk samples.

Figure 33

Forest plot of absolute risk differences in antibiotic resistance to penicillins for Staphylococcus spp. isolates in milk samples.

Figure 34. Forest plot of absolute risk differences in antibiotic resistance to sulfonamides for Staphylococcus spp. isolates in milk samples.

Figure 34

Forest plot of absolute risk differences in antibiotic resistance to sulfonamides for Staphylococcus spp. isolates in milk samples.

Figure 37. Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Enterobacteriaceae isolates in faecal samples, stratified by intervention type.

Figure 37

Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Enterobacteriaceae isolates in faecal samples, stratified by intervention type.

Figure 38. Forest plot of absolute risk differences of antibiotic resistance to cephalosporins for Enterobacteriaceae isolates in faecal samples, stratified by intervention.

Figure 38

Forest plot of absolute risk differences of antibiotic resistance to cephalosporins for Enterobacteriaceae isolates in faecal samples, stratified by intervention.

Figure 39. Forest plot of absolute risk differences of antibiotic resistance to penicillins for Enterobacteriaceae isolates in faecal samples, stratified by intervention.

Figure 39

Forest plot of absolute risk differences of antibiotic resistance to penicillins for Enterobacteriaceae isolates in faecal samples, stratified by intervention.

Figure 40. Forest plot of absolute risk differences of antibiotic resistance to quinolones for Enterobacteriaceae isolates in faecal samples, stratified by intervention.

Figure 40

Forest plot of absolute risk differences of antibiotic resistance to quinolones for Enterobacteriaceae isolates in faecal samples, stratified by intervention.

Figure 41. Forest plot of absolute risk differences of antibiotic resistance to sulfonamides for Enterobacteriaceae isolates in faecal samples, stratified by intervention type.

Figure 41

Forest plot of absolute risk differences of antibiotic resistance to sulfonamides for Enterobacteriaceae isolates in faecal samples, stratified by intervention type.

Figure 44. Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 44

Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 45. Forest plot of absolute risk differences of antibiotic resistance to glycopeptides for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 45

Forest plot of absolute risk differences of antibiotic resistance to glycopeptides for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 46. Forest plot of absolute risk differences of antibiotic resistance to macrolides for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 46

Forest plot of absolute risk differences of antibiotic resistance to macrolides for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 47. Forest plot of absolute risk differences of antibiotic resistance to penicillins for Enterococcus spp isolates in faecal samples, stratified by intervention.

Figure 47

Forest plot of absolute risk differences of antibiotic resistance to penicillins for Enterococcus spp isolates in faecal samples, stratified by intervention.

Figure 48. Forest plot of absolute risk differences of antibiotic resistance to streptogramins for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 48

Forest plot of absolute risk differences of antibiotic resistance to streptogramins for Enterococcus spp. isolates in faecal samples, stratified by intervention.

Figure 51. Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 51

Forest plot of absolute risk differences of antibiotic resistance to amphenicols for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 52. Forest plot of absolute risk differences of antibiotic resistance to macrolides for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 52

Forest plot of absolute risk differences of antibiotic resistance to macrolides for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 53. Forest plot of absolute risk differences of antibiotic resistance to penicillins for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 53

Forest plot of absolute risk differences of antibiotic resistance to penicillins for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 54. Forest plot of absolute risk differences of antibiotic resistance to quinolones for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Figure 54

Forest plot of absolute risk differences of antibiotic resistance to quinolones for Campylobacter spp. isolates in faecal samples, stratified by intervention.

Copyright © World Health Organization 2017.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “The translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Bookshelf ID: NBK487956

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (462K)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...